University of Kentucky

UKnowledge
Theses and Dissertations--Pharmacology and
Nutritional Sciences

Pharmacology and Nutritional Sciences

2014

A Brief Elevation of Serum Amyloid A is Sufficient to Increase
Atherosclerosis
Joel C. Thompson
University of Kentucky, joel.thompson@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Thompson, Joel C., "A Brief Elevation of Serum Amyloid A is Sufficient to Increase Atherosclerosis"
(2014). Theses and Dissertations--Pharmacology and Nutritional Sciences. 7.
https://uknowledge.uky.edu/pharmacol_etds/7

This Doctoral Dissertation is brought to you for free and open access by the Pharmacology and Nutritional
Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacology and
Nutritional Sciences by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Joel C. Thompson, Student
Dr. Lisa R. Tannock, Major Professor
Dr. Howard Glauert, Director of Graduate Studies

A BRIEF ELEVATION OF SERUM AMYLOID A IS SUFFICIENT TO
INCREASE ATHEROSCLEROSIS

Dissertation

A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Medicine at the University of Kentucky

By
Joel C. Thompson
Lexington, KY
Director: Lisa R. Tannock, MD, Professor of Medicine
Lexington, KY
2014
Copyright © Joel C. Thompson 2014

A BRIEF ELEVATION OF SERUM AMYLOID A IS SUFFICIENT TO
INCREASE ATHEROSCLEROSIS

Cardiovascular disease is now the leading cause of death worldwide. Serum
amyloid A (SAA), a positive acute phase reactant, along with C-reactive protein is
used clinically as a marker of cardiovascular disease risk. However, recent data
has shed light on a possible causal role of SAA in the development of
atherosclerosis, the most pervasive form of cardiovascular disease. Several
inflammatory diseases such as diabetes and obesity are known to confer
increased risk of developing cardiovascular disease. Individuals with these
diseases all have modest but persistent elevation of SAA. To determine if SAA
caused the development of atherosclerosis, apoe-/- chow fed mice were injected
with either an adenoviral vector expressing human SAA1 (ad-hSAA1), a null
adenoviral vector (ad-Null) or saline. Human SAA levels rapidly increased, albeit
briefly then returned to baseline within 14 days in mice that received ad-hSAA1.
After 16 weeks, mice that received ad-hSAA1 had significantly increased
atherosclerosis compared to controls on the aortic intimal surface (p<0.0001),
aortic sinus (p<0.05) and the brachiocephalic artery (p<0.05). According to the
“response to retention” hypothesis; lipoprotein retention by vascular wall
proteoglycans is a key initiating event in the development of atherosclerosis. We
previously reported that SAA-stimulated vascular smooth muscle cells expressed
biglycan with increased glycosaminoglycan chain length and increased binding
affinity for low density lipoprotein. To further test the role of biglycan on the
development of atherosclerosis we generated biglycan transgenic mice. These
mice were crossed to the ldlr-/- mouse on a C57BL/6 background and fed a proatherogenic western diet for 12 weeks. There was a significant increase in
atherosclerotic lesion area on the aortic intimal surface (p<0.05) and the aortic

sinus (p<0.006), as well as a significant correlation between vascular biglycan
content and aortic sinus atherosclerotic lesion area (p<0.0001). These data
demonstrate that transiently increased SAA resulted in increased atherosclerosis
compared to control mice, possibly via increased vascular biglycan content. In
support of this we found that biglycan transgenic mice had significantly increased
atherosclerosis compared to wildtype controls, likely through increased lipid
retention in the vascular wall.
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Chapter 1: Introduction
1.1

Initiation of atherosclerosis: competing hypotheses

1.1.1

The Response to injury

The single initiating event in the development of atherosclerosis has yet to
be defined. Over the years many theories have been tested providing a great
deal of information regarding the origins of atherosclerotic plaques in the
vasculature. One of the pioneers in the study of early atherosclerosis was Dr.
Russell Ross. He championed the “response to injury” hypothesis of
atherosclerosis which proposed that some insult to the endothelium represented
the key initiating event in atherosclerosis. He argued that endothelial dysfunction
caused by mechanical stress, homocysteine exposure, oxidized LDL, toxins as
well as other triggers was sufficient to establish the beginnings of fatty streak
formation, the first histologically visible manifestation of atherosclerosis. The
body of his work focused on the activation of inflammatory signaling cascades in
response to these endothelial insults (1). However, morphological analysis of
lesion development revealed several concepts that contradict the theories of
Ross et al. First, most lesions maintain an intact endothelial layer until they
become very advanced, rupture-prone atheromas (2). Second, endothelial
denudation, which is a known side effect of balloon angioplasty, does not result
in plaque formation (3). Another major component of the “response to injury”
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theory related to endothelial cells is the expression of vascular adhesion
molecules. Vascular cell adhesion molecule 1 (VCAM1) and intercellular
adhesion molecule 1 (ICAM1) are both expressed on the luminal surface of
endothelial cells in response to injury or inflammatory stimuli within the vessel
wall. While this response is certainly necessary for the overall homeostasis of
the vessel as it recruits leukocytes to points of injury, it can also be very
problematic. If the stimuli driving adhesion molecule expression is itself
dysregulated, the signaling of inflammatory cells will lead to excess leukocyte
recruitment and inflammation; and the potential for disease development as seen
in the progression of atherosclerosis. Inflammatory cytokines such as TNF-α and
IL-1 are capable of stimulating the expression of adhesion molecules in
endothelial cells; however, some signal must be present to drive the expression
and secretion of these cytokines (4). The identification of the underlying driving
force for inflammatory cytokine secretion is one area where the “response to
injury” hypothesis remains incomplete. The “response to injury” also presents
ox-LDL as a molecule capable of causing endothelial dysfunction (5). The
limitation of this idea is that the plasma environment inhibits most oxidation of
lipoproteins (6). Moreover, any amount of oxidized LDL found in circulation is
cleared very rapidly by the liver (7), thus it’s not likely to interact with the vessel
wall in appreciable amounts. It’s been demonstrated that LDL and other
lipoproteins naturally flux in and out of the vessel wall (8), suggesting that
lipoprotein flux is not pathogenic; however, the retention of those lipoproteins
might be. All of the above mentioned processes, endothelial dysfunction,
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adhesion molecule expression and the presence of ox-LDL are very important in
the progression of atherosclerosis; however, the evidence simply does not
support the idea that any of them are individually sufficient to initiate the
development of atherosclerosis.

1.1.2

The Response to Retention

The gaps in explaining the development of atherosclerosis through
vascular injury lead to the “response to retention” hypothesis of early
atherosclerosis. It surmises that the retention of lipoproteins in the
subendothelial space by vascular proteoglycans is an initiating event in the
development of atherosclerosis (9). Much of the early evidence for retention as
an initiating event in atherosclerosis was done in rabbit models. When made
rapidly hypercholesterolemic via bolus injection of LDL, arterial lipid content
increased within minutes to hours. Importantly, it was shown that the rate limiting
step in lipid accumulation in the vessel wall was a lack of egress, meaning the
LDL particles were being retained by some component of the subendothelial
compartment (10). The molecules most implicated in the retention of LDL in the
vessel wall are proteoglycans, which have negatively charged
glycosaminoglycan side chains capable of interacting with positively charged
motifs on apolipoprotein B (11). Evidence for this interaction has been
demonstrated both histologically and biochemically.
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The importance of this lipoprotein/proteoglycan interaction on the
development of atherosclerosis was demonstrated by a series of experiments
using mice transgenic for several mutations of apolipoprotein B. The mutations
involved amino acid substitutions of several sites on the apolipoprotein B
molecule identified as important in either LDL receptor binding or proteoglycan
binding (11). In mice with apolipoprotein B lacking the ability to bind to
proteoglycans, the degree of atherosclerosis was significantly less than those
mice with normal proteoglycan binding, independent of the cholesterol levels.
This implied that elevated total cholesterol was not sufficient to cause severe
early atherosclerosis independent of proteoglycan binding (12). However, followup work related to proteoglycan binding defective apolipoprotein B demonstrated
that, given enough time, the degree of atherosclerotic lesion development in all
groups ultimately reached the same magnitude. Furthermore, lipoprotein lipase
was identified to play a key role in bridging lipoproteins to proteoglycans in
middle to late developing lesions; events that take place well after lipid retention
has been established (13). Thus, lipoprotein/proteoglycan interaction is
important for the initiation of atherosclerosis; however, it may not be required as
other mechanisms such as molecules capable of bridging lipoproteins to
proteoglycans have been identified (13).
1.1.3

Evidence that lipoprotein retention precedes
inflammation

Franks et al demonstrated lipoprotein retention prior to histologically
relevant lesion formation utilizing freeze-etch electron microscopy. Lipid droplets
4

in the subendothelial space of hyperlipidimic apoe-/- aortas, but not C57BL/6
control aortas, were clearly evident as early as three weeks of age (14).. Franks
work was greatly extended by Nakashima et al, who investigated the progression
of early atherosclerosis in human coronary arteries. They established a scoring
system, with a scale of 0-3, based on the degree of lipid deposition in the
subendothelial space of the arteries. Lesions scoring zero presented with only
diffuse intimal thickening, a physical change in the vessel wall marked by
increased matrix deposition. No lipid deposition was observed in lesions scored
with zero. Conversely, lesions with a score of three had extensive lipid retention
with accompanying macrophage infiltration. Their data demonstrated that lipid
retention was only identified after diffuse intimal thickening, implying that matrix
deposition was a key initiating event in the development of atherosclerosis.
Once lipid retention progressed to some critical level, macrophages began to
infiltrate the vessel wall, appearing to translocate exclusively from the luminal
side of the vessel (15). Thus, their chronology of early atherosclerosis was:
increased matrix deposition followed by lipid retention then followed by
macrophage infiltration (16).

The evidence clearly pointed to atherosclerosis as

a disease of retention followed by inflammation.

1.2

Biglycan

1.2.1

Biglycan regulation

5

With regards to the “Response to Retention” hypothesis, the proteoglycan
most associated with lipid retention in both human and murine atherosclerotic
lesions is the small leucine rich proteoglycan biglycan (17). The gene for this
small proteoglycan is located on the X chromosome, where it encodes a highly
conserved core protein with a mass of about 42 kDa (18). Biglycan possesses
two glycosaminoglycan side chains composed of chondroitin or dermatan sulfate
disaccharide repeats (19), attached to the N-terminus of the core protein (20).
The promoter region of the biglycan gene possesses AP2 sites, IL-6 response
elements, an NF-κB site and a TGF-beta negative element. Actual regulation of
the biglycan gene varies greatly depending on the cell type and developmental
stage (21). For instance, in chondrocytes retinoic acid down regulates biglycan;
however, in skeletal muscle retinoic acid had no effect on biglycan but did
increase expression of the closely related proteoglycan decorin (22). It has also
been clearly demonstrated that TGF-beta increases biglycan in most cell types
(23) including glomerular mesangial cells (24). In osteoblastic cells, IGF-1 and
IGF-2, both known to stimulate bone development have also been shown to
increase biglycan expression (25).

1.2.2

Biglycan and the extracellular matrix

Within the vasculature, biglycan is expressed in many different cell types.
However, the predominant site of synthesis is the vascular smooth muscle cells,
where it is secreted as part of the extracellular matrix. When initially
characterized some 30 years ago, biglycan’s normal physiological function within
6

the matrix, particularly bone, was thought to be interacting with and stabilizing
matrix components such as collagen (26) and elastin fibers (27). Thus, biglycan
was assumed to play an integral, albeit inert, role within the extracellular
compartment. The importance of biglycan in stabilizing the extracellular matrix
was demonstrated recently in biglycan deficient mice. These mice had an
increased incidence of spontaneous aortic dissection and rupture due primarily to
weakly organized collagen fibrils which resulted in aortas with low tensile
strength (28). The rate of aortic dissection and rupture in biglycan deficient mice
was further exacerbated by infusion of angiotensin II (29). Biglycan’s residence
in the extracellular matrix underscores many of its important, recently identified
biological functions. Many studies now suggest that biglycan is a regulator of
growth factors and inflammatory cytokines such that it is now regarded as a
member of the innate immune system (30). Proteolytic enzymes such as bone
morphogenic protein 1 (BMP1), matrix metalloproteinases (MMP) and granzyme
B can cleave biglycan’s core protein releasing it from the extracellular matrix
where it then acts as a “danger signal” ligand for many different receptors.
Mitogen activated protein kinase p38 (MAPK), extracellular signal-regulated
kinase (ERK) and nuclear factor kappa-light chain enhance of activated B cells
(NF-κB) are rapidly phosphorylated when soluble biglycan binds to Toll like
receptor 2 and 4. Macrophages stimulated via biglycan/Toll like receptor
interaction had a profoundly increased expression of macrophage inflammatory
protein-1α (MIP-1α) and monocyte chemoattractant protein-1(MCP-1) resulting in
the recruitment of more monocyte/macrophages to sites of tissue injury (31) (32).
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Biglycan has also been shown to induce inflammation by clustering Toll like
receptors with the receptor P2X 7 to activate the NLRP3 inflammasome ultimately
leading to the secretion of mature IL-1β (33). Biglycan has certainly been
established as a key mediator of tissue injury derived inflammation; however,
recent reports also demonstrated that biglycan can activate the adaptive immune
response in macrophages and dendritic cells. Once bound to Toll like receptors,
biglycan was able to upregulate CXCL13, a major B cell attractant and biomarker
of autoimmune inflammatory diseases (32).
1.2.3

Biglycan in atherosclerosis

Biglycan is the molecule most often associated with retention of lipids in
early atherosclerotic lesions in both humans and mice (17). Biglycan is
upregulated by several cytokines that have been implicated in the development
of atherosclerosis including angiotensin II and TGF-β (34, 35). Studies have
demonstrated that biglycan is present in both human and murine atherosclerotic
lesions. Interestingly, in human coronary arteries, versican is the predominant
proteoglycan. However, when human coronary atherosclerotic lesions were
examined for lipoprotein and proteoglycan co-localization, biglycan was the
proteoglycan most likely to co-localize with the lipoproteins apolipoprotein E and
apolipoprotein B. Versican was associated with regions of low lipoprotein
content (36). In both apoe-/- and ldlr-/- mouse models, biglycan was present at all
stages of aortic sinus lesion development co-localized with apolipoprotein A-I and
apolipoprotein B lipoproteins (37). Interestingly, biglycan stimulated by cytokines
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associated with atherosclerosis had longer, more negatively charged GAG
chains (38). Such a modification would allow for a very strong ionic interaction
between biglycan and the positive amino acid moieties found on lipoproteins
such as apolipoprotein B (11). Thus, biglycan, possibly by way of retaining proatherogenic lipoproteins, is likely to play a role in the development of
atherosclerosis. Interestingly, the evidence that biglycan is capable of activating
the innate immune system; and the importance of inflammation in the
development of atherosclerosis (39), likely provides a second possible means by
which biglycan is atherogenic. As previously stated, TGF-β is a potent initiator of
biglycan synthesis such that TGF-β warrants further discussion.

1.3

Transforming Growth Factor β

1.3.1

The TGF-β superfamily

TGF-β is a member of the eponymously named TGF-β superfamily of
cytokines and growth hormones that play an immense role in all aspects of
development and maintenance of most organisms. The family is comprised of
several TGF-β isoforms as well as bone morphogenic proteins, activins, and
nodals (40). These molecules play a role in processes such as cell proliferation
and differentiation, which represent key elements of TGF-β’s embryonic
developmental programming. However, it is TGF-β’s role in synthesis of
extracellular matrix and regulation of immune cells that link it profoundly to the
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development of atherosclerosis (41). There are three isoforms of TGF-β
represented within this family, being TGF-β1, TGF-β2 and TGF-β3. They are all
products of different genes and share approximately 80% sequence homology
(42). To date, the vast majority of data collected on these isoforms pertains to
TGF-β 1 function. Given its capacity to affect so many aspects of cellular
homeostasis, TGF-β’s expression and regulation are tightly controlled both within
the cell and once secreted to the extracellular compartment.

The TGF-β protein

is synthesized as a pro-protein. The pro-protein segment of the molecule must
be cleaved prior to TGF-β being exported; however, it remains ionically
associated with TGF-β and the two molecules are secreted as a latent complex
(43). Once in the extracellular compartment TGF-β is sequestered to the
extracellular matrix by several molecules including biglycan. TGF-β remains
inactive until it is proteolytically cleaved by one of several matrix proteases,
including plasmin, integrins but most often thrombospondin 1 (44). Once
liberated from the matrix, TGF-β becomes a ligand for the transforming growth
factor β type two receptor (TβRII). This TGF-β complex then interacts with one of
several transforming growth factor β type I receptors to initiate downstream
signaling within the cell. Several members of the SMAD protein family are
primarily responsible for canonical TGF-β signal transduction within the cell;
however, other pathways have been identified. SMAD 2 & 3 are TGF-β receptor
specific effector molecules that become phosphorylated upon TGF-β ligand
binding and receptor complex formation. The phospho-SMAD2/3 then
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complexes with SMAD4 ultimately acting as a nuclear transcription factor driving
the expression of TGF-β target molecules (45).

The investigation of TGF-β function is made quite difficult by the fact that
when knocked out, mice do not live more than a few weeks as a result of
profound inflammation within the major organs, thus genetically derived loss of
function studies are nearly impossible to perform (46). Furthermore, modulation
of TGF-β in vivo involves the use of inhibitory antibodies and soluble receptors to
inactivate the cytokine while in circulation. This fails to address the paracrine
and autocrine capacities of TGF-β within the compartment for which it was
synthesized and secreted (47). This is why TGF-β’s physiological functions are
loosely characterized as requiring the right cell type, the right cytokine
concentration and the right timing (48).

1.3.2

TGF-β and atherosclerosis

TGF-β proteins are synthesized in many cells including most cells present
in atherosclerotic lesions such as vascular smooth muscle cells, leukocytes and
endothelial cells (48). A simplistic description of TGF-β action, particularly
related to atherosclerosis, is to categorize it as anti-inflammatory and pro-fibrotic.
However, again TGF-β signaling is very spatially and temporally dependent.
Under homeostatic conditions, TGF-β inhibits cell proliferation and helps to
maintain healthy extracellular matrix as its actions act in opposition to matrix
degrading proteins such as matrix metalloproteinases(MMP) (45). TGF-β has
11

been shown to maintain vascular smooth muscle cells in a contractile state, thus
preventing the cells from adopting a synthetic phenotype which would result in
increased matrix deposition (49). Increased matrix accumulation including the
deposition of the proteoglycan biglycan have been shown to associate with the
early development of atherosclerosis by increasing the retention of lipoproteins in
the vessel wall, thus setting off the cascade of events leading to fatty streak
formation and ultimately the development of atheromas (50). Thus, maintaining
homeostatic levels of TGF-β is key step in maintaining vascular wall integrity;
however, many molecules with links to cardiovascular disease are capable of
increasing TGF-β levels. Diseases such as diabetes are known to stimulate
increased TGF-β expression (51). Interestingly, individuals with diabetes also
have a greater risk of developing cardiovascular disease (52). Beyond disease
states, several cytokines such as angiotensin II have been shown to increase
plasma TGF-β levels. Ldlr-/- mice infused with angiotensin II for 28 days via alzet
pump implantation had a rapid 3 fold increase in TGF-β levels by day three.
These mice also had increased atherosclerosis compared to saline infused mice.
When a subset of these mice was concurrently treated with angiotensin II and the
TGF-β neutralizing antibody 1D11, the induction of TGF-β was prevented.
Furthermore, the mice receiving TGF-β inhibition had less atherosclerosis
quantified in the aortic sinus (53). Thus, TGF-β appeared to directly stimulate the
development of atherosclerosis.
However a consensus on TGF-β’s role in atherosclerosis is as yet
undetermined. Work by Mallat et al, using a pan-TGF-β inhibitory antibody to
12

decrease circulating levels of TGF-β1, TGF-β2 and TGF-β3, resulted in
increased plaque size in apoe-/- male mice. They also reported a much more
inflamed plaque with increased macrophage content and decreased collagen
fibers (54). Increased inflammation and a lack of fibrous continuity within a lesion
represents the hallmark of an unstable, clinically significant atheroma (55).
Conversely, Lutgens et al reported that TGF-β inhibition in apoe-/- male mice via
injection of a soluble TGF-β receptor resulted in a dramatic change in lesion
cellularity with an influx of inflammatory cells. However, when lesions were
analyzed for atherosclerosis, the group that received TGF-β inhibition had a
striking decrease in lesion area (56). In summary, three models of TGF-β
inhibition and atherosclerosis were studied. One suggested that TGF-β was antiatherogenic; two suggested that TGF-β was pro-atherogenic; however the two
suggesting TGF-β is pro-atherogenic differed greatly in the resulting inflammatory
effects of TGF-β inhibition. Obviously, there is still a great deal of work to be
done to understand TGF-β’s role in atherosclerosis.
1.4

Serum amyloid A

1.4.1

SAA background

Serum amyloid A (SAA) is a family of highly conserved apoproteins.
They are expressed in almost every vertebrate animal studied to date, ranging
from humans, goats, fox, to the arctic char, a salmon-like fish (57). This implies a
significant evolutionary importance for this family of proteins. Humans have four
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unique isoforms of SAA and mice have 5, each with some allelic variation. The
genes for the human SAA isoforms are located on chromosome 11p15.1 within
150kb of each other (58). The genes for murine SAA are also located within very
close proximity to one another, spanning approximately 45kb on chromosome 7.
This chromosome locus is considered to be syntenic to the chromosome locus of
human SAA (59). Murine and human SAA’s are categorized based on their
responsiveness to inflammatory or infectious stimuli. Mice and humans share
two homologous acute phase isoforms of SAA; SAA1 and SAA 2 in humans and
SAA1.1 and SAA 2.1 in mice, which are synthesized primarily in the liver (60).
Though mice and humans have varying numbers of alleles of both of these
genes, human SAA1 is considered homologous to murine SAA1.1 and human
SAA2 is considered homologous to murine SAA2.1. During an acute phase
response (APR) these protein variants can increase in concentration up to 1000
fold over baseline levels (61). Though the exact role for this substantial increase
is not fully appreciated, it is thought to play a major role in activating the immune
system to respond to acute stimuli. As an APR resolves there is an equally
rapid resolution of the serum concentrations of the acute phase SAA’s.

Mice

possess another less understood acute phase SAA, SAA3. This particular
isoform is only modestly homologous to murine SAA1.1 and 2.1, sharing
approximately 60% of the other acute forms’ sequence (62). This is considered
an extrahepatic acute SAA, expressed in macrophage and adipose tissue that
does not contribute to circulating levels of SAA (63). Murine SAA3’s homologue
in the human genome was considered a pseudogene possessing a single
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nucleotide mutation that inserts a premature stop codon into the sequence. This
sequence disruption was thought to be sufficient to prevent the protein from
being synthesized (64) ;however, studies have begun to identify human SAA3 by
RT-PCR (65). Whether human SAA3 actually produces a functional gene
product has yet to be determined. Both humans and mice have another isoform
of SAA that is considered constitutively active as its serum levels do not change
in the presence of acute inflammatory or infectious stimuli. These SAA’s have an
additional eight peptides generating a monomeric SAA about 2kDa larger than
the acute isoforms (66). Though both humans and mice express these
constitutive isoforms, their function remains unknown.

SAA has been most broadly investigated as the circulating precursor to
complex amyloid plaques that form in tissue throughout the body during
amyloidosis (67). Surprisingly though, little is known structurally about the SAA
family of proteins. It had previously been reported that SAAs likely existed in an
alternating helix- β−sheet conformation based on predictive structural analysis
(68). However, recently, Jinghua et al have identified several structural
components of human SAA that have helped to explain some the molecule’s
functions. First and foremost, they identified that the protein contains four alpha
helices and no β-sheet motifs. Also, the structure has some homology to
apolipoprotein E which is an interesting discovery given that SAA and
apolipoprotein E have some similar binding capacities involving the bridging of
lipoproteins to proteoglycan rich matrix (69). They also revealed that the two
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regions of helix 1 and 3 in each monomer thought to be amyloidogenic are buried
in the native conformation of human SAA1, thus implying that SAA does not
naturally aggregate into amyloid plaques (70). Though the vast majority of work
with SAA is focused on amyloidosis, a very robust body of literature is being
cultivated investigating SAA’s role in cardiovascular disease.

1.4.2

SAA and cardiovascular disease

Modestly elevated SAA is a characteristic of many inflammatory diseases
such as diabetes and obesity (71) (72). Individuals who suffer from such
diseases have an increased risk of developing heart disease, particularly
atherosclerosis, though the exact etiology remains unknown (73). SAA and high
sensitivity C-reactive protein (hs-CRP) have long been regarded as very useful
markers of inflammation, and both are quite robustly associated with
cardiovascular disease outcomes (74). hs-CRP is more widely accepted as a
better marker for overall cardiovascular risk (75); however, SAA may be a better
indicator of the extent of disease present as shown by data analyzed as part of
the Women’s Ischemia Syndrome Evaluation (WISE) trial (74).
Not until recently though has SAA’s potential causal role in atherosclerosis
been investigated. Though SAA’s exact native biological role in both humans
and mice is not fully understood, several potential pathologic features of SAA as
they relate to the development of atherosclerosis have been identified. Lee at al
demonstrated that human monocytes in culture responded to SAA stimulation
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with a dose dependent increase in CCL2, a potent monocyte chemoattractant
found in atherosclerotic lesions. They extended this work to reveal that SAA
acted through the receptor FPRL1 to activate NF-κB to drive the observed CCL2
synthesis (76). We too have demonstrated that SAA’s effects on biglycan
synthesis in vascular smooth muscle cells was dependent upon interaction
between SAA and the FPRL1 receptor as competitive inhibition of the receptor
rendered the cells insensitive to exogenous SAA (38). It is well known that
recruitment of inflammatory cells, particularly macrophages, into developing
lesions is a key step in the progression of atherosclerosis from a disease of lipid
retention to a disease of inflammation. Once in the lesion, macrophage uptake of
modified lipid particles results in the formation of lipid laden foam cells (9). Lee
et al continued their work on SAA to demonstrate that not only could SAA
increase the recruitment of macrophages to lesions via increased CCL2
expression, it could also directly stimulate the transition from macrophage to
foam cell via LOX1 receptor activation (77). Work by others has revealed that
not only can SAA recruit macrophages, but other leukocytes as well (78).

SAA

is an apoprotein most commonly associated with HDL. Furthermore during
inflammation, SAA becomes the predominant protein associated with HDL
particles (79). One of the main athero-protective functions of HDL is to promote
reverse cholesterol transport (RCT), which involves the trafficking of peripheral
lipids to the liver for excretion either as bile or feces (80). SAA was previously
thought to reduce RCT though it may simply be SAA associated inflammation
driving that effect (81), as a recent study utilizing a murine model in which both
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SAA1.1 and SAA2.1 were knocked out revealed that the effect of inflammation
on RCT was independent of SAA (82). The previously mentioned events
surrounding atherosclerosis are not regarded as initiating events, but reveal a
role for SAA in progression of the disease.

Beyond its physiological effects on cytokines and inflammatory cells, SAA
has also been visualized via immunohistochemistry in atherosclerotic lesions colocalized with lipoproteins such as apoA-I and apoB in two murine models of
atherosclerosis (83). Interestingly SAA was also shown to interact with a class of
molecules of particular interest in our lab, proteoglycans, and in particular
biglycan. Studies have revealed that HDL’s rate of retention within
atherosclerotic lesions via interaction with vascular biglycan is directly related to
the amount of SAA found associated with the HDL particle (84).

The question of SAA’s direct role in increasing atherosclerosis was first
addressed by the work of Dong et al when they overexpressed SAA in apoe-/mice via injection of a lentiviral vector encoding murine SAA1.1. Their data
revealed that increased SAA directly accelerated the progression of
atherosclerosis independent of all other risk factors. Thus SAA for the first time
was shown to be directly causal in the development of atherosclerosis. Their
mechanistic assessment of SAA mediated atherosclerosis found that SAA drove
the expression of vascular cell adhesion molecules thus increasing inflammatory
cell recruitment to the lesion (85). This phenomenon is thought to contribute to
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progression, but not initiation, of atherosclerosis as lipid deposition has been
shown to precede leukocyte infiltration (15). Thus, their model did not address
SAA’s capacity to initiate the disease.

Previous work from our lab also investigated the role of SAA in the
development of atherosclerosis. Vascular smooth muscle cells treated with
recombinant SAA demonstrated a dose dependent increase in proteoglycan
synthesis, primarily due to an increase in biglycan synthesis. The SAA
stimulated biglycan molecule had longer, more negatively charged
glycosaminoglycan side chains (38). This modification of biglycan is thought to
increase LDL retention (17). This effect on biglycan synthesis was shown to be
TGF-β dependent as TGF-β inhibition nullified the observed increase in biglycan
synthesis. We repeated the experiment in a murine model of atherosclerosis by
injecting apoe-/- mice with an adenoviral vector containing cDNA for human
SAA1, a control adenoviral vector (ad-Null) or saline. Mice injected with adhSAA1 had dramatically increased plasma SAA after only three days.
Interestingly, these mice also had dramatically increased TGF-β over the same
timeframe. After 28 days, western blot analysis of whole aortas demonstrated
increased biglycan content in ad-hSAA1 injected mice, possibly predisposing the
aorta to increased lipid retention and atherosclerosis (38).

This work

represented the foundation of the experiments presented in this thesis.
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1.5

Rationale for the studies presented

Inflammation associated diseases such as diabetes and obesity are
present in a very large portion of westernized societies. Individuals suffering with
such maladies have an increased risk of developing cardiovascular disease
compared to age matched healthy peers though the exact etiology remains
elusive. A useful diagnostic tool to evaluate the extent of inflammation in these
patients are assays for the plasma proteins hs-CRP and SAA. Though much
attention was given to hs-CRP and its potential causal role in atherosclerosis, no
definitive causal association was determined. Conversely, early working into
SAA’s biology within the vasculature revealed several features that could
potentiate cardiovascular disease. SAA is found in lesions associated with
apolipoprotein B and apolipoprotein A1 containing lipoproteins, it is chemotactic
for molecules found in atherosclerotic lesions and it’s elevated in diseases known
to confer greater risk of developing atherosclerosis. One molecule for which SAA
exudes potent synthetic upregulation is the small leucine rich, ubiquitously
expressed proteoglycan biglycan (38). Cells treated with recombinant SAA
produced more biglycan, possessing long GAG chains and having a greater
affinity for LDL particles. SAA’s effects on biglycan synthesis were dependent on
the action of TGF-β as inhibition of the cytokine with an inhibitory antibody
resulted in no increase in biglycan synthesis compared with cells treated with
SAA alone. The previous experiments were conducted using a recombinant SAA
molecule from Peprotech Inc. (NJ, USA). This variant of SAA is a combination
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of human SAA 1 and 2 with two amino acid substitutions. Many of the proinflammatory effects attributed to SAA have been deduced using this molecule
for in vitro culture system analysis. Recently, the Peprotech recombinant human
SAA was directly compared with another Peprotech SAA variant, recombinant
human SAA 1. This molecule was based entirely on the human SAA 1 protein;
however, it too has an amino acid substitution, thus a direct comparison to
endogenous human SAA was not made. The authors claim that the commonly
used recombinant human SAA molecule is distinctly more inflammatory than the
SAA variant based on human SAA 1 alone. Their data suggested that
recombinant human SAA 1 did not activate IL-8 or NF-κB to the same magnitude
as the commonly used recombinant human SAA. They conclude by stating that
experiments using the recombinant forms of SAA should also be performed using
endogenous forms for verification of the results (86). We feel confident that the
in vitro work using recombinant human SAA reflects SAA’s true biological
functions as the data was corroborated in vivo using apoe-/- male mice, injected
with an adenoviral vector containing the cDNA for human SAA1. These mice
exhibited a rapid induction of SAA with a concordant increase in TGF-β. Western
blot analysis 28 days after treatment revealed that there was an increase in
vascular biglycan content. Based on the response to retention hypothesis, an
increase in modified biglycan within the subendothelial space of atherosclerosis
prone arteries would increase the potential for increased lipid retention and
atherosclerosis. However, definitive evidence that an SAA mediated increase in
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biglycan content would result in more plaque burden remained to be determined.
Thus we set out to investigate the following model by testing five hypotheses:

 SAA, expressed chronically would result in increased atherosclerosis
 A brief increase in plasma SAA would also increase the development
of atherosclerosis via upregulation of vascular biglycan content
 Increased vascular biglycan is individually sufficient to increase
atherosclerosis independent of inflammation
 Vascular biglycan is required for the development of atherosclerosis
 TGF-β is a necessary intermediate between SAA and biglycan in the
development of SAA mediated atherosclerosis
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Chapter 2: Materials and Methods

2.1

Murine Models
The work presented in this thesis utilized several murine models including

the apolipoprotein E deficient (apoe-/-) mouse, the recombination activating gene
1 x apolipoprotein E (rag1-/- x apoe -/-) double knockout, the biglycan transgenic
and the biglycan x apolipoprotein E (bgn-/- x apoe -/-) double knockout. The
apoe -/- and the rag1 -/- mice were purchased from The Jackson Laboratory (stock
# 002052 and stock # 003729, respectfully), and crossed in house to generate
the rag1-/- x apoe -/- mouse. The apoe -/- deficient mouse was utilized for all the
SAA mediated atherosclerosis studies for two reasons. First, apolipoprotein E
can bridge lipoproteins to proteoglycans in a manner similar to SAA, thus
interpretation of SAA’s role in lipoprotein retention would be difficult to isolate in
the presence of apolipoprotein E. Second, the apoe -/- mouse spontaneously
develops atherosclerosis without the need for a high fat/high cholesterol diet, as
these diets are capable of elevating SAA levels. The deletion of the rag1 gene
established a mouse unable to generate mature B and T lymphocytes, meaning
the mouse had very little immune function present. When the apoe -/- mouse was
crossed to the rag1-/- mouse, it created an apoe -/- mouse tolerant to repeated
adenoviral injections.

Vascular biglycan content was elevated in mice with increased plasma
levels of SAA. However, SAA has multiple mechanisms by which it is suspected
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to increase atherosclerosis. Therefore, in the presence of SAA it was not
possible to determine the exact individual role that elevated biglycan had on the
development of atherosclerosis. Therefore, the biglycan transgenic mouse was
generated. This mouse allowed elevated biglycan to be investigated
independent of the other possible confounding factors associated with elevated
SAA. The biglycan transgene construct was created by inserting human biglycan
cDNA downstream of the smooth muscle alpha actin promoter in the pBS-HSMA
construct. This construct was generously provided to us by Sasamura et al (87).
It was immediately sent to Xenogen Biosciences (NJ, USA), were they performed
microinjections of the construct into fertilized C57BL/6 ova. Three founders, all
male were returned to the University of Kentucky for further breeding. No
offspring resulted from in-house breeding with the male founders. As a result,
one male was shipped to Charles River Laboratory (MI, USA) for in vitro
fertilization of C57BL/6 female mice. Viable pups were produced, returned to the
University of Kentucky and crossed with ldlr-/- mice. Transgenic mice were
identified by PCR using the following primer sequences: forward primer, 5′-TCC
TGG GAC TTC ACC CTG GA-3′ and reverse primer, 5′-TTG AAG TCA TCC TTG
CGG AG-3′. Mice positive for the transgene were bred together to establish the
transgenic line, mice negative for the transgene were bred to establish wildtype
control mice for the studies. Interestingly, the difficulty we experienced
establishing the biglycan transgenic mouse was not experienced by the original
investigator. Sasamura reported no fertility issues in generating this mouse. We
postulate that the increased biglycan content led to increased matrix deposition
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and blockage of the vas deferens resulting in infertility of the three male
founders.
Preliminary studies revealed that elevated SAA resulted in increased
vascular biglycan content which was hypothesized to increase atherosclerosis
(38). However, the absolute necessity of biglycan in SAA mediated
atherosclerosis was not known, therefore the bgn-/- x apoe -/- double knockout
was generated. The bgn-/- mouse was kindly provided by Dr. Marian Young
(National Institutes of Health). ). bgn-/o males carry only a single copy of the
gene for biglycan, located on the X chromosome. In order to generate the bgn-/x apoe -/- double knockout mouse, males deficient in bgn-/- were crossed to
female apoe -/- deficient mice establishing biglycan wildtype males(bgn+/o) and
biglycan heterozygous (bgn+/-) females, that were now all heterozygous for
apolipoprotein E (apoe +/-). Male biglycan wildtype by apolipoprotein E
heterozygous (bgn+/o x apoe +/-) were crossed to female biglycan x apolipoprotein
E heterozygous mice (bgn+/- x apoe +/-). The offspring from this cross provided
the first opportunity to establish a male biglycan knockout mouse that was either
deficient or heterozygous for apolipoprotein E (bgn-/o x apoe +/- or bgn-/o x apoe -/). The previous cross also established a female mouse that was heterozygous
for biglycan but deficient in apolipoprotein E (bgn+/- x apoe -/-). The double
knockout mouse was established by crossing the male biglycan deficient x
apolipoprotein deficient (bgn-/o x apoe -/-) to the female biglycan heterozygous x
apolipoprotein E knockout (bgn+/- x apoe -/-).
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All studies were initiated in eight week old mice housed in specific
pathogen free caging systems with 12 hour light/dark cycles in accordance with
the University of Kentucky Animal Care and Use Committee.

2.2

Human SAA1 adenoviral vector
The human SAA1 and null adenoviral vectors were generated

and kindly provided by Nancy Webb, University of Kentucky. Briefly, cDNA for
human SAA1 was cloned into the plasmid vector pAdCMVlink. Plasmids which
contained properly inserted cDNA were co-transfected into HEK293 cells with
adenoviral DNA from H5.100CMVlacZ (88). After 15 days, plaques were
selected and screened by PCR. Those plaques possessing SAA DNA were then
further purified and used to produce a large scale preparation of the adenoviral
vector stocks (89).

To commence the sustained SAA studies, eight week old

male rag1-/- x apoe-/- mice were injected via the lateral tail vein every 21 days with
1.5 x 1011 plaque forming units of an adenoviral vector encoding human
SAA1(ad-hSAA1), a control empty adenoviral vector (ad-Null) or saline as
previously reported (38). The rag1-/- x apoe-/- mice were utilized as the deletion
of the rag1 gene made the mice tolerant to repeated viral injections necessary to
facilitate chronic expression of SAA (model of sustained elevation in SAA). For
the brief elevation of SAA, eight week old apoe-/- male mice, also from Jackson
Laboratory, received a single lateral tail vein injection of 1.5 x 1011 plaque forming
units of ad-hSAA1, ad-Null or saline (model of brief elevation in SAA). The bgn-/x apoe-/- mice as well as the apoe-/- mice which received virus concurrently with
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TGF-β inhibition also received a single injection of ad-hSAA1, ad-Null or saline
as described above. All experiments involving adenoviral vectors were
performed in biological safety level II (BSL2) isolation cabinets following the
Division of Laboratory Animal Research’s standard operating procedures. To
perform the injections, adenoviral stocks, either ad-hSAA1 or ad-Null, were
transported on dry ice to the appropriate procedure room within the vivarium,
equipped with a BSL2 safety cabinet. The mice were assessed for overall health
as part of a pre-enrollment screen prior to initiating the study. Once all mice
were deemed healthy, the supplies (syringes, alcohol swabs, etc.) were arranged
in the hood in such a way as to minimize the time required to perform the
injections as the virus was only stable for a few minutes once resuspended in
sterile PBS. For the injection, 100µl of sterile saline diluted viral stock was drawn
into a 0.3cc insulin syringe with a 28 ½ gauge needle. The mouse was then
restrained in a rotating tail injector (Braintree Scientific; MA, USA) and the tail
was warmed with a chemical hand warming pouch for 30 seconds. The lateral tail
vein was visualized and the resuspended virus was injected into the mouse. In
the event that the vein became compromised do to mouse movement or needle
infiltration, the contralateral vein was quickly accessed and injected. The
restraint was then loosened and hemodynamic control at the injection site was
gained if necessary. The mouse was then returned to its home cage and
monitored for 20 minutes post injection.
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2.3

TGF-β Neutralizing Antibodies

Inhibition of TGF-β was utilized to determine the necessity of TGF-β in
SAA mediated atherosclerosis. We had previously shown in vitro that SAA
increased biglycan in a TGF-β dependent manner (38). However, it has yet to be
determined if TGF-β is required for SAA mediated upregulation of biglycan in vivo
and/or atherosclerosis; thus, we designed an experiment where SAA levels
would be elevated in the presence or absence of TGF-β. Inhibition of TGF-β
was achieved using R and D Systems TGF-β 1, 2, 3 antibody (clone 1D11,
MAB1835). This antibody was selected as it was very specific to TGF-β, and did
not affect other members of the TGF-β superfamily (90). apoe-/- mice received
antibody injections once concurrently with the administration of the adenoviral
vectors; ad-hSAA1 or ad-Null. The procedure for administration of SAA is
described in Section 2.2, Human SAA1 adenoviral vector. That procedure
concluded with the mouse being removed from the tail vein injector and returned
to the home cage. For this experiment, the mouse would receive the tail vein
injection, then immediately be removed from the restraint and be physically
restrained by scruffing the excess skin between the shoulder blades while
concurrently grasping the tail. This position provided easy access to the midline
of the ventral surface of the mouse. Once sufficient control of the animal was
achieved it was injected intraperotineally with 1D11 antibody (2mg/kg) in sterile
PBS via a 0.3cc syringe with a 28 ½ gauge needle. As a control for the TGF-β
inhibition, each study included a group of mice similarly injected with the 13C4
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irrelevant control antibody (2mg/kg; GenScript, Piscataway, NJ, USA) also via
the intraperotineal route. The 13C4 antibody was directed against Shigella toxin
and shown not to interfere with TGF-β signaling (91). Mice were then returned to
their home cage and monitored for 20 minutes.

2.4

Diets

For the studies investigating the role of SAA overexpression, all mice were
maintained on normal rodent chow (product #8604) from Harlan Teklad.
Throughout the study, mice had ad libitum access to food and water. The
Biglycan transgenic mice, crossed to the ldlr-/- mouse on a C57BL/6 background,
were fed “western diet” from Harlan Teklad (TD.88137). The notable changes in
this diet vs. standard chow are the high percent of calories from fat (42% vs.
4.7% in normal chow) and 0.2% cholesterol. The western diet was utilized for
the transgenic studies as the biglycan transgenic x ldlr-/- mouse required dietary
modification to develop atherosclerosis (92). Because of the high fat content of
the “western” diet, it would spoil quite rapidly. As such, fresh food was provided
every three to four days. Mice ate approximately 4 grams of food per day.

2.5

Blood collection

For all studies, blood was collected via submandibular vein route for all
samples except the terminal blood collection. The submandibular approach is
preferred when small volumes of blood are required with short intervals between
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collections. In the SAA studies, blood was collected on days 0, 1, 3, 7, 10, 14,
21, 28 and then weeks 8, 12 and 16, depending on the duration of the study.
The increased frequency of collection of blood at the beginning of the studies
allowed for the accurate determination of human SAA, murine SAA and TGF-β
levels, as these molecules tend to have rapid induction with an equally rapid
reduction in plasma concentration. However, the increased frequency of blood
collection required that we staggered the mice such that not all mice were bled at
each timepoint. For example, if a study group had 9 mice; then the first 3 would
be bled on day 0, the next three on day 1 and the final three on day 3. The
staggered approach to blood collection prevented the use of repeated measures
analysis as the data did not represent each mouse at each timepoint. For the
biglycan transgenic study, blood was collected at day 0 and then at weeks 4, 8
and 12. To collect the blood, unanesthatized mice were scruffed by the excess
skin between the shoulder blades to immobilize the mouse’s head. The
submandibular vein typically resides just caudal and slightly superior to the
sebaceous gland located just caudal to the mandible. The skin was lanced
superficially with a 5mm stainless steel lancet (Medipoint; NY, USA). As blood
began to flow it was collected in EDTA treated tubes. Once an appropriate
volume of blood had been collected, pressure was applied to the wound until
hemostasis was achieved. The animal was then returned to its home cage and
monitored for 20 minutes. Terminal blood was collected by cardiac puncture for
all studies. At the conclusion of all studies, mice were adequately anesthetized
and a thoracotomy performed to gain access to the heart. A 1.0cc syringe with a
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28 gauge needle was inserted into the right ventricle and approximately 1ml of
blood was collected. All blood samples were stored on ice until they could be
centrifuged to separate the plasma from the red blood cells. All analyte
measurements were performed on plasma.

2.6

Plasma analyte measurements

Blood samples were collected throughout all studies described in this
thesis. For studies involving the sustained overexpression of SAA, the
concentration of the following analytes were measured: human and mouse SAA,
TGF-β, total cholesterol and triglycerides. For studies involving the brief
overexpression of SAA, the concentration of the following analytes were
measured: human and mouse SAA, TGF-β, total cholesterol, triglycerides and
liver alanine transaminase. For the biglycan transgenic study, TGF-β, total
cholesterol and triglycerides were measured. Human and mouse SAA were
measured by species specific ELISA from Anogen Corp. (EL10015) and
Invitrogen (KMA0021) respectfully. TGF-β was measured by the Promega TGFβ1 Emax ImmunoAssay System (G7590). Cholesterol (Cholesterol E) and
triglycerides (L-Type TG M) were measured via colorimetric assay using kits from
Wako Diagnostics (Richmond, VA). Alanine transaminase was measured using
Therma Scientific Infinity ALT/GPT assay reagent. All assays were performed
per manufacture’s instruction. A BioRad X-mark spectrophotometric plate reader
was utilized to determine analyte concentration.
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2.7

Western Blot

Vascular tissue was homogenized in Trizol reagent (Invitrogen; NY, USA)
and proteins purified per the manufacturer’s protocol. Proteins were treated with
Chondroitinase ABC to digest the glycosaminoglycan side chains of the
proteoglycans overnight at 37°. Total protein was measured using the Lowry
method and equal amounts of protein from each sample was then separated on
4-20% precast gradient gels (Bio-Rad; CA, USA) at 150 volts for 45 minutes.
The samples were then transferred to PVDF membranes at 100 volts for 90
minutes. The membranes were then probed for biglycan (AF2667, R & D
systems, 1:1000) or the loading control β-actin (A2066, Sigma-Aldrich; MO, USA,
1:1000). The membranes were then incubated with horseradish peroxidase
conjugated secondary antibody at 1:25,000 dilution and proteins detected by film
exposure using West Pico Super Signal chemiluminescent detector (34080,
Pierce; IL, USA). Densitometry was performed on individual bands using
imageJ (NIH, USA) software’s western blot analysis plug-in.

2.8

Atherosclerosis analysis

The aortic sinus, brachiocephalic artery and whole aorta from the
ascending arch to the iliac bifurcation were collected at the conclusion of all
studies. Aortic roots and brachiocephalic arteries were frozen in a cryogenic
cutting compound and sectioned at 10um thickness using a Leica CM1850
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cryostat. Collection of aortic root sections began once all three valve leaflets of
the aortic valve were in view and proceeded distally away from the valves
towards the ascending aorta. Sections were collected in series such that each
aortic root was collected on eight slides containing nine sections each. Each
section on an individual slide was 80µm from the previous section. Given that
the brachiocephalic artery is longer than the aortic root, a total of 12 sections per
slide were collected across eight slides. The start point of brachiocephalic artery
collection was the convergence of the right subclavian artery and the right
common carotid. Once this point was reached sections were collected proximally
towards the heart. Again, the sections were 80µm apart on each slide.

Prior to staining, aortic root and brachiocephalic sections were allowed to
dry at room temperature and then fixed in 10% neutral buffered formalin for 5
minutes. Lipids were visualized by staining the sections with Oil Red O’ (O0625,
Sigma-Aldrich; MO, USA) for 20 minutes as previously described (34). Sections
were then counterstained with Mayer’s Hematoxyin (26043, Electron Microscopy
Sciences; PA, USA) and coverslipped. Aortic root (4x magnification) and
brachiocephalic artery (10x magnification) sections were visualized using a Nikon
Eclipse 80i bright field microscope and Nikon Digital Sight Ri1 camera. One slide
from the aortic root and brachiocephalic artery from each mouse was quantified,
thus nine aortic root sections and twelve brachiocephalic sections were
quantified per mouse. Using Nikon NIS elements software suite, all lesions per
tissue section were traced and summed to generate the total lesion area per
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section. After all nine (aortic root) or twelve (brachiocephalic) sections were
measured, they were averaged to give an average lesion area per mouse. Data
were then presented as the average lesion area for each mouse as well as the
group average.

Whole aortas were cleaned in vivo and removed from the mice and fixed
in 10% neutral buffered formalin overnight, then transferred to saline prior to en
face analysis to soften the tissue. Using very fine tipped spring scissors, the
vessels were first cut along the greater curvature of the aortic arch distal to just
past the left subclavian bifurcation. The aorta was then cut along the lesser
curvature from the ascending arch to the iliac bifurcation. The tissue was then
pinned en face in premade black wax dishes and stained with 1% Sudan IV
(S4261, Sigma-Aldrich; MO, USA) dissolved in 70% ethanol/acetone for 20
minutes. The aortas were washed several times with PBS, and then visualized
using a Nikon SMZ800 stereo microscope with a Nikon Digital Sight DSFi1
camera.

For en face analysis, the aortic arch is analyzed. To establish the total
arch area, a line extended 3mm from the left subclavian artery bifurcation distally
along the aorta. A line is then created perpendicular to the aorta along the end of
the 3mm line. Any tissue superior to this line was considered part of the total
aortic arch area and used in quantification. The first en face measurement is the
total area achieved by simply tracing the entire perimeter of the tissue previously
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identified as arch. Then each lesion is traced and surface area summed to
establish total lesion area. Data were presented as the percent lesion area for
each mouse as well as the mean for each group. All data was analyzed by 1way ANOVA.

2.9

Fluorescent Immunohistochemistry

Aortic root and brachiocephalic sections were immunostained with
antibodies against murine biglycan (AF2667,R & D systems R & D systems,
1:50), apolipoprotein B (K23300R, Biodesign, 1:50), Perlecan (BMDV10187,
Accurate, 1:100), CD68 (ab53444, Abcam, 1:100) and smooth muscle alpha
actin (NB300-978, Novus, 1:50) as previously described (53). Sections were
then probed with host specific secondary antibodies conjugated to either 488nm
or 594nm fluorophore (Jackson ImmunoResearch) and counterstained with
Vectashield mounting media containing DAPI (H-1200, Vector Labs). Sections
were visualized fluorescently via a Nikon Eclipse 80i fluorescent microscope or a
Leica AOBS TCS SP5 inverted laser scanning confocal microscope.

2.10

Bright field Immunohistochemistry

Aortic root sections were incubated with primary antibodies for murine
biglycan (AF2667, R & D systems), then incubated with a biotinylated secondary
antibody (Jackson ImmunoResearch). The presence of biglycan antigen was
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visualized using an AEC chromogen kit (SK-4205, Vector Labs) and
counterstained with Meyers hematoxilyn (26043, Electron Microscopy Sciences;
PA, USA). Images were captured using a Nikon Eclipse 80i light microscope at
4x and 20x magnification.

2.11

LDL binding assay with apoe-/- VSMC’s

Primary vascular smooth muscle cells were isolated from ~3 week old
apolipoprotein E (apoe-/-, stock # 002052) mice and grown to confluence without
passaging. Cells were incubated with SAA (25µg/ml) isolated from acute phase
murine plasma (kindly provided by Frederick and Maria de Beer, University of
Kentucky) ± TGF-β neutralizing antibody 1D11 (10µg/ml, MAB1835, R & D
Systems; Minneapolis, MN) or control antibody 13C4 (10µg/ml, GenScript,
Piscataway, NJ) for 24 hours. The cells were washed and then labeled with
Alexa-fluor 594 (A10237; Life Technology; Grand Island, NY) labeled LDL
(0.5mg/ml) for 2 hours at 4°C. Cells were washed twice in cold PBS, fixed in 4%
formaldehyde and then coverslipped with Vectasheild mounting media containing
DAPI (H-1200, Vector Labs). The cells were then imaged using a Nikon Eclipse
80i fluorescent microscope. For each experimental condition, 5 20x fields were
captured in both the 594nm and the 405nm channels and quantified using
ImageJ software (93). LDL binding is expressed as Alexa-fluor 594 surface area
normalized to DAPI surface area from 5-10 20x microscope fields. Negative
controls included wells with no cells and/or no Alexa-fluor 594 labeled LDL.
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2.12

Fast performance liquid chromatography

Terminal plasma samples (50ul) were separated for analysis of lipoprotein
cholesterol content chromatographically using a BioRad Biologic Duoflow FPLC
machine equipped with a Superose size exclusion column. Fractions, each
containing about 200µl of eluate were collected on a BioRad Biofrac fraction
collector and assayed for total cholesterol as previously described (93) using a
Wako Diagnostic Cholesterol E colorimetric assay kit.

2.13

Statistical analysis

Statistical differences were assessed by one-way ANOVA to assess
effects of treatment with ad-hSAA1, ad-Null or saline; or two-way ANOVA to
assess effects of ad-hSAA1 or ad-Null ± 1D11 or 13C4. LDL binding was
assessed using a student’s t-test. Linear regression was used to assess the
relationship between vascular biglycan and aortic sinus atherosclerosis. P<0.05
was considered statistically significant.
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Chapter 3: Sustained elevation of SAA results in increased
atherosclerosis
3.1

Results

We previously investigated the effect of SAA on vascular smooth muscle
cells. Cells treated with increasing doses of SAA had a dose-dependent
increase in biglycan synthesis as well as increased binding affinity of biglycan for
LDL. SAA’s effect on biglycan synthesis was recapitulated in vivo in apoe-/- mice
injected with an adenoviral vector containing the gene for human SAA (38).
Interestingly, the effect of SAA was inhibited by concurrently treating the cells
(38) or mice (Thompson et al, in submission) with a TGF-β inhibitory antibody.
We hypothesized, based on the response to retention hypothesis, that the
increased vascular biglycan would lead to increased lipoprotein retention in the
vessel wall stimulating the development of atherosclerosis. To test this
hypothesis, rag1-/- x apoe -/-mice were injected with ad-hSAA1, ad-Null or saline
once every 21 days for 12 weeks. rag1 deficiency was necessary for the animals
to tolerate repeated viral injections. These mice had persistently elevated human
SAA throughout the study (Figure 3.1A) with no difference in murine SAA
between groups at any timepoint (Figure 3.1B), indicating that our experimental
manipulations did not induce an endogenous inflammatory response. We
previously determined in vitro that SAA's increase in vascular biglycan content
was TGF-β dependent (38). Thus we measured TGF-β in all groups to determine
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in vivo whether elevated SAA had any effect on TGF-β levels. Mice that received
ad-SAA also had increased TGF-β compared to ad-Null and saline injected mice
throughout the study (Figure 3.2).Consistent with Dong et al, ad-hSAA1 treated
mice had increased atherosclerosis on the aortic intimal surface (Figure 3.3A,
p<0.001) and within the brachiocephalic artery (Figure 3.3B, p<0.05) compared
with ad-Null or saline groups. There was a strong trend towards increased
atherosclerosis in the aortic root in ad-hSAA1 treated mice compared to ad-Null
or saline groups; however it did not reach statistical significance (Figure 3.3C,
p=0.09). Biglycan and apoB co-localized in aortic sinus lesions, further
supporting the response to retention hypothesis (Figure 3.4). The induction of
human SAA had no effect on plasma cholesterol or triglycerides (Figure 3.5AB).
Lipoprotein distribution was measured using fast performance liquid
chromatography and did not differ between any of the groups (Figure 3.5C).
Body weight did not differ at any point throughout the study (data not shown).
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Figure 3-1: Human, but not murine SAA increased when mice
received multiple injections of ad-hSAA1 compared to
control mice
rag1-/- x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null
(open squares) or saline (black triangles) every 21 days (as indicated by the
red numerals on the x axis) and fed normal rodent chow for 12 weeks. A.
Mice receiving ad-hSAA1 had a dramatic, persistent elevation of human
SAA1. Shown are mean ± SEM for n=2-5 per group. B. Murine SAA did not
increase nor did it differ between groups throughout the study. Shown are
mean ± SEM for n=2-7 per group.
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Figure 3-2: Murine TGF-β increased in mice injected with ad-hSAA1
rag1-/- x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null
(open squares) or saline (black triangles) every 21 days (indicated by red
numerals on the x axis) and fed normal rodent chow for 12 weeks. Ad-hSAA1
injected mice had persistently increased TGF-β throughout the study
compared to mice injected with ad-Null or saline. Shown are means ± SEM
from n= 2-6 mice/group per timepoint.
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Figure 3-3: Atherosclerosis increased in mice chronically
overexpressing human SAA
-/rag1 x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null
(open squares) or saline (black triangles) every 21 days and fed normal rodent
chow for 12 weeks. Ad-hSAA1 injected mice had increased atherosclerosis
on the aortic intimal surface (A) and in the brachiocephalic artery (B). There
was a trend towards increased atherosclerosis in the aortic root that did not
reach significance (C). Data points represent individual mice with the
horizontal bar representing means of n =4-16 mice per group analyzed by 1way ANOVA and Tukey’s multiple comparisons test. *p<0.05, **p<0.01.
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*

Figure 3-4: Biglycan and apolipoprotein B colocalized in rag1-/- x
apoe -/- murine aortic sinus lesions
rag1-/- x apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline
every 21 days and fed normal rodent chow for 12 weeks. Representative
confocal image of a shoulder lesion in an aortic root from an ad-hSAA1
injected rag1-/- x apoe-/- mouse (magnified 40x). ApoB and biglycan were
visualized with green and red fluorescent antibodies respectfully. Colocalization is indicated by yellow. Image is representative of 4-5 mice per
group. Asterisk is within the lumen of the vessel, scale bar 50µm.
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Figure 3-5: Chronically elevated hSAA1 did not affect plasma lipids
rag1-/- x apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline
every 21 days and fed normal rodent chow for 12 weeks. After 12 weeks,
there was no difference in plasma cholesterol (A, n=9-11 mice per group) or
triglycerides (B, n=8-10 mice per group). A & B data presented as mean ±
SEM analyzed by 1-way ANOVA and Tukey’s multiple comparisons test.
Lipoprotein distribution was measured in plasma from n=4-5 mice per group
collected after 12 weeks of study and separated by FPLC. No differences
were observed between groups [C, ad-hSAA1 (black circles), ad-Null (open
squares) or saline (black triangles), data presented as mean ± SEM].
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3.2

Discussion:

Persistently elevated human SAA in rag1-/- x apoe-/- mice resulted in
increased atherosclerotic lesion area. There were no differences between
groups in cholesterol or triglyceride levels, and the adenovirus did not induce
endogenous inflammation demonstrated by the lack of elevation of murine SAA.
Mice that received ad-hSAA1 had dramatically elevated TGF-β compared to mice
receiving ad-Null or saline.

Biglycan is thought to be the proteoglycan most responsible for the
retention of pro-atherogenic lipoproteins in the vessel wall leading to the
development of atherosclerosis (9). Thus we propose that at least one
mechanism by which SAA is pro-atherogenic is by induction of vascular biglycan
in a TGF-β dependent manner leading to increased retention of atherogenic
lipoproteins. The co-localization of apolipoprotein B with biglycan in a shoulder
lesion of the aortic sinus supports this concept.
However, the exact role of TGF-β in atherosclerosis remains quite
controversial. Mallat et al used an inhibitory antibody to decrease TGF-β content
and observed increased plaque size in apoe-/- male mice. They also reported a
much more inflamed plaque with increased macrophage content and a decrease
in collagen fibers (54). Similarly, Lutgens et al reported that TGF-β inhibition in
apoe-/- male mice via injection with a soluble TGF-β receptor resulted in a
dramatic change in lesion cellularity with an influx of inflammatory cells.
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However, when lesions were analyzed for atherosclerosis, the group receiving
TGF-β inhibition had a striking decrease in lesion area (56). To add to the
confusion surrounding TGF-β in atherosclerosis, we have previously shown that
ldlr-/- mice infused with angiotensin II (angII) for 28 days had increased vascular
biglycan content. We also demonstrated that the increased biglycan content was
TGF-β dependent, (similar to SAA induction of biglycan) as the inhibition of TGFβ in the setting of angII infusion resulted in less vascular biglycan and less
atherosclerotic lesion area. However, there was no change in inflammatory cell
content within lesions (53). Thus further study into the role of elevated TGF-β in
our SAA overexpression model is necessary to elicit its exact role in SAA
mediated atherosclerosis.

Our results support the previous findings from Dong et al (85) that SAA is
proatherogenic. In their study, murine SAA was overexpressed by lentiviral
vector leading to significantly increased atherosclerosis on the aortic intimal
surface and the aortic sinus in chow fed apoe-/- mice. The increased
atherosclerosis coincided with upregulation of vascular adhesion molecules and
chemotactic factors capable of increasing leukocyte migration into
atherosclerosis susceptible regions of arteries. The study presented here
addresses events prior to vascular wall leukocyte infiltration, including vascular
wall remodeling and lipoprotein retention (9). Our model indicated that SAA is
acting on the vasculature prior to the cascade of inflammatory events observed in

46

Dong’s work. We have shown that treatment with SAA, both in vitro and in vivo,
increased vascular biglycan content leading to increased lipid retention.

In further support of the hypothesis that lipid retention precedes
inflammatory infiltration of atherosclerosis prone regions of arteries, Nakashima
et al investigated human coronary vessels to establish a chronology of events
thought to provoke atherosclerosis development. In a very effective use of
histology and immunohistochemistry, their study demonstrated very convincingly
that lipid retention preceded leukocyte infiltration in the development of lesions in
human coronary arteries. They investigated vessels from individuals whose
average age of death was 36 years. These individuals died from trauma or other
non-cardiovascular causes. In all the lesions investigated, diffuse intimal
thickening (DIT), the non-pathologic remodeling of the vessel wall preceded both
lipid and macrophage infiltration. They identified several locations in the
coronary artery were there was DIT but no lesion development; however, they
did not find regions with lesions and no DIT. The deposition of matrix was clearly
an initial step in the development of atherosclerosis. They also demonstrated
that lipid accumulation became quite substantial in regions with DIT prior to
macrophage infiltration suggesting that lipid retention preceded the inflammatory
response in the development of atherosclerosis, strongly supporting our model of
atherosclerosis development (15). Thus, our work taken together with Dong’s
data suggest that SAA’s actions leading to the development of atherosclerosis
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may be multifactoral in nature, playing a role in both early (lipid retention) and
more advanced lesion development (inflammatory infiltration).
Changes in the vessel wall, such as diffuse intimal thickening prior to fatty
streak formation are thought to be paramount in the development of
atherosclerosis in regions of the vessel prone to lipid deposition (94). In diffuse
intimal thickening there is a dramatic increase in subendothelial matrix deposition
including proteoglycans such as biglycan which we observed in our model and is
thought to play a major role in lipid retention in atherosclerotic lesions. The
vasculature is divided into two groups based on the presence or absence of
diffuse intimal thickening. First are the atherosclerosis prone vessels such as the
aorta, carotids and coronaries. In humans, these vessels all exhibit diffuse
intimal thickening as early as late fetal development (16). Conversely
atherosclerosis resistant arteries are located much farther down the vascular tree
and tend to deliver blood to specific organs such as the splenic and hepatic
arteries. Observations of these vessels reveal no diffuse intimal thickening at
any timepoint observed (16).

Though there is not always atherosclerosis at

sites of diffuse intimal thickening, in the human vasculature there are is always
subendothelial matrix expansion including increased biglycan at sites of
atherosclerosis (15).

Beyond the observation that SAA increases biglycan deposition in a
proatherogenic manner, it has been reported that SAA co-localized with both
biglycan and apolipoprotein B containing lipoproteins (83). SAA has amino acid
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clusters that allow it to simultaneously bind proteoglycans and lipoproteins which
could make SAA directly atherogenic via directing the binding of lipoproteins to
biglycan in the subendothelial space of atherosclerosis prone arteries(95) .
Certainly more research is required to demonstrate that SAA is directly mediating
such an interaction. Thus, SAA could contribute to atherosclerosis through
multiple mechanisms, including vascular wall remodeling, by directing
chemotaxis of circulating leukocytes to the region of lipoprotein retention (85),
and by potentially bridging lipoproteins to vascular wall proteoglycans (83) (95).
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Chapter 4: Briefly elevated SAA resulted in increased
atherosclerosis
4.1

Results

We have clearly shown that sustained elevation of SAA is proatherogenic
(Chapter 3), providing a possible link between chronic inflammatory diseases and
the increased risk of cardiovascular disease. However, many people have
dramatic, albeit brief increases in SAA via an acute phase response to infection
or injury (96-98). Survivors of such an event have increased long term all cause
mortality, including cardiovascular disease. Thus we sought to determine if a
brief increase in SAA also increased atherosclerosis, as we have previously
demonstrated that even a brief increase in SAA resulted in increased vascular
biglycan content (38). To test the hypothesis that even brief exposure to
increased SAA was proatherogenic, apoe-/- mice received a single injection of
Ad-hSAA1, Ad-Null or saline at the initiation of the study. The mice that received
ad-hSAA1 had a dramatic increase in human SAA, albeit not to the level seen in
an acute phase response. The increased human SAA returned to baseline levels
in less than two weeks (Figure 4.1A). Murine SAA did not differ between groups
at any timepoint (Figure 4.1B). In mice that received ad-hSAA1 there was a
transient increase in TGF-β that resolved in a similar timeframe to human SAA
(Figure 4.2). Interestingly, despite only observing a transient increase in human
SAA levels, these mice developed significantly more atherosclerosis on the aortic
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intimal surface (Figure 4.3A, p<0.001), the aortic root (Figure 4.3B, p<0.05) and
the brachiocephalic artery (Figure 4.3C, p<0.05) compared with ad-Null or saline
treated mice. This result could be explained by the fact that mice receiving adhSAA1 had increased vascular biglycan content at the conclusion of the study
even though SAA was only increased for a brief period of time (Figure 4.4). The
induction of human SAA had no effect on terminal plasma lipids (Figure 4.5AB).
Lipoprotein distribution was measured using fast performance liquid
chromatography, and no differences were observed between groups (Figure
4.5C). Body weight measured at the completion of the study did not differ
between groups (Figure 4.6A). Alanine transaminase (ALT) was measured for
the first two weeks of the study to determine if injecting the mice with an
adenoviral vector that traffics to the liver led to hepatitis. There was a brief
increase in ALT in the mice receiving ad-hSAA1 that did not exceed the normal
range of 5-60 U/L typically observed in mice (Figure 4.6B). The ad-Null and
saline groups did not deviate from baseline ALT values. Aortic root sections
were double stained for BGN and apoB and immunofluorescent analysis
demonstrated colocalization of apolipoprotein B with biglycan within the vascular
wall (Figure 4.7). To determine if the retention of ApoB containing lipoproteins by
vascular matrix is a direct result of increased plasma SAA, primary apoe-/- aortic
vascular smooth muscle cells were incubated with mouse SAA for 24 hours,
followed by incubation with Alexa-594 labeled LDL for two hours. Cells treated
with SAA had a 4 fold increase in LDL binding compared to cells not treated with
SAA (Figure 4.8A). To determine if the role of TGF-β in SAA mediated
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lipoprotein retention, the experiment was repeated with the additional conditions;
SAA + TGF-β inhibitory antibody 1D11 or SAA + 13C4 irrelevant control
antibody. In the absence of TGF-β signaling, the amount of bound LDL was
significantly reduced compared to SAA treated cells (Figure 4.8B).

52

Human SAA (mg/L)

A
50

ad-hSAA1
ad-Null
Saline

40
30
20
10
0
0

10

20

30

Day

Mouse SAA (mg/L)

B
50

ad-hSAA1
ad-Null
Saline

40
30
20
10
0
0

10

20

30

Day
Figure 4-1: Human, but not murine SAA increased in mice that received a
single injection of ad-hSAA1 compared to control mice
-/apoe male mice were injected at day 0 with ad-hSAA1 (black circles), ad-Null
(open squares) or saline (black triangles) and fed normal rodent chow for 16
weeks. Mice receiving a single injection of ad-hSAA1 had a dramatic albeit
transient increase in human SAA1. (A, data presented as mean ± SEM for n=23 mice per group). All groups had a small, transient increase in murine SAA.
(B, data presented as mean ± SEM for n=2-6 mice per group).
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Figure 4-2: TGF-β increased dramatically in mice overexpressing
SAA
-/apoe male mice were injected with ad-hSAA1 (black circles), ad-Null (open
squares) or saline (black triangles) and fed normal rodent chow for 16 weeks.
TGF-β was transiently but dramatically increased in ad-hSAA1 mice compared
to ad-Null or saline mice. Data presented as means ± SEM from n= 4-6 mice
per group.
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Figure 4-3: A brief elevation of human SAA1 was associated with
increased atherosclerosis after 16 weeks
-/apoe male mice were injected with ad-hSAA1, ad-Null or saline and fed
normal rodent chow for 16 weeks. Atherosclerosis was measured at three
sites: the aortic intimal surface (A), the brachiocephalic artery (B) and the
aortic sinus (C). Data points represent individual mice with the horizontal bar
representing means of n =4-16 mice per group analyzed by 1-way ANOVA with
Tukey’s multiple comparisons. *p<0.05.
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Figure 4-4: A brief increase in human SAA1 resulted in increased
vascular biglycan content after 16 weeks.
-/apoe male mice were injected with ad-hSAA1, ad-Null or saline and fed normal
rodent chow for 16 weeks. Carotid arteries were collected and immunoblotted for
biglycan (BGN) or actin (A) then analyzed by densitometry using ImageJ
software (B). Each lane shows protein from an individual mouse; densitometry
shows means ± SEM for 5-7 mice per group analyzed by one-way ANOVA and
Tukey’s multiple comparisons. *p<0.05.
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Figure 4-5: Briefly elevated human SAA1 did not alter plasma lipids or
lipoprotein distribution
apoe-/- male mice were injected once with ad-hSAA1 , ad-Null or saline. After 16
weeks, total cholesterol (A) and triglycerides (B) did not differ between groups. Data
presented as mean ± SEM for 4-18 mice per group analyzed by one-way ANOVA and
Tukey’s multiple comparisons. The distribution of lipoproteins did not differ between
groups (C), data represent mean ± SEM for n=2-9 mice per group, ad-hSAA1 (black
circles), ad-Null (open squares), saline (black triangles).
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Figure 4-6: Body weights did not differ; however, ALT increased
slightly as a result of increased human SAA1 compared to
control mice.
-/apoe male mice were injected once with ad-hSAA1, ad-Null or saline. Body
weight did not differ between groups at the conclusion of the study (A). Data
represent mean ± SEM for n=4-11 mice analyzed by one-way ANOVA and
Tukey’s multiple comparisons. Mice injected with ad-SAA had a slight increase
in ALT liver enzymes compared to mice injected with either ad-Null or saline
(B). Data represent mean ± SEM for n=2-3 mice per group.
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Figure 4-7: Biglycan and apolipoprotein B co-localized in aortic
sinus lesions of mice overexpressing human SAA1.
An atherosclerotic lesion in an aortic root from an ad-hSAA1 injected
apoe-/- mouse was double stained for apoB (green) and biglycan (red).
Co-localization is indicated by yellow. Shown is a confocal image
magnified 63X, representative of 4 mice. The asterisk indicates the lumen
of the aortic sinus. Scale bar 10µm.
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Figure 4-8 VSMC cultures treated with murine SAA had increased TGF-β
dependent LDL binding
apoe-/- aortic VSMC cultures were treated with vehicle or SAA for 24 hours, then
washed and incubated with Alexa-594 labeled LDL (0.5mg/ml) for 2 hours. LDL
binding is expressed as Alexa-fluor 594 surface area normalized to DAPI surface
area quantified by fluorescent microscopy using ImageJ software (NIH, USA). A.
SAA treated cells had significantly increased LDL binding compared to controls.
Data analyzed by student’s t-test. B. To determine the role of TGF-β in LDL
retention, apoe-/- aortic VSMCs were treated with vehicle, SAA or SAA with the TGFβ neutralizing antibody 1D11 or control antibody 13C4. 1D11 prevented the SAA
increase in LDL binding; there was no effect of 13C4. Data are presented as
mean±SEM from 5-10 20x regions/condition analyzed by one-way ANOVA and
Tukey’s multiple comparisons. *p<0.05 **p<0.01. Controls included cells treated
with 1D11 inhibitory antibody or 13C4 antibody without concurrent SAA treatment.
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4.2

Discussion
In this model, we investigated the potential atherogenic effect of a single

transient increase (<14 days) of ad-hSAA1, such as seen in an intensive care
hospitalization. Similar to mice with sustained overexpression of SAA, mice in
this study had increased atherosclerosis at all three vascular sites investigated.
Furthermore biglycan and apolipoprotein B co-localized in aortic sinus lesions of
mice exposed to a brief increase in SAA. Also similar to the sustained elevation
group, these mice had no metabolic variability in such lipid parameters as
cholesterol, triglycerides or lipoprotein distribution to explain the difference in
atherosclerosis. Thus, this increase in atherosclerosis is presumably driven
directly by increased SAA. It is noteworthy to point out that the atherosclerosis
data for the aortic intimal surface appears to be biphasic. The data for the mice
receiving ad-hSAA1 appears to form two unique groups, one with a much higher
average lesion area than the other, suggesting that the mice in the lower group
did not respond to the administration of ad-hSAA1 to the same degree as those
in the high atherosclerosis group. This could be considered a confounding factor
in concluding that SAA is universally causing the development of atherosclerosis.
However, the aortic sinus and brachiocephalic atherosclerosis data looks
normally distributed such that the aortic intimal surface is likely an anomaly.

This study investigated the role of acutely increased SAA and its effect on
atherosclerosis. This induction of SAA, though lower in total plasma SAA
concentration, is similar in duration to what a human could experience during an
acute phase response to infection or injury. However, in our study, we utilized an
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adenoviral vector to mediate increased SAA gene expression rather than LPS or
sodium nitrate, which would increase plasma SAA, but also broadly stimulate the
innate immune system. The adenoviral method avoided introducing the milieu of
inflammatory cytokines seen in LPS or sodium nitrate stimulated immune
response that would make it nearly impossible to elicit SAA’s individual effect on
atherosclerosis. A better understanding of the impact of brief but significant
inflammation is necessary as clinical data suggests that individuals suffering
acute severe illness resulting in intensive hospitalization have increased mortality
post discharge (96-98) . These patients have increased SAA as part of the APR
experienced in the hospital, thus it is plausible that the increased mortality,
particularly related to cardiovascular disease could be driven by the downstream
effects of elevated SAA. This idea is supported by a study investigating
myocardial infarct (MI) and progression of atherosclerosis. Dutta et al
investigated the potential for MI, with the associated APR, to accelerate the
development of atherosclerosis. The common dogma of atherosclerosis
following MI is that the disease progression continued at the pre- MI rate. This
assumption failed to consider the risk of acute inflammation, thus they
investigated the possibility that MI related inflammation could alter the
progression of atherosclerosis. Using an apoe-/- mouse model of left coronary
artery ligation, they compared atherosclerosis development between infarcted
and sham operated animals. The data demonstrate that mice in the MI group
had a subsequent increase in atherosclerosis, likely the result of the acute phase
response to the infarct leading to increased monocyte recruitment to the
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developing lesions (99). Our work here investigated SAA, a single component of
the acute phase response and its role in the development of atherosclerosis. It is
certainly possible that the increased atherosclerosis observed in Dutta’s study
was in part the result of increased SAA during the post MI acute phase response.
SAA is known to be chemotactic for macrophages, thus SAA in the lesion could
have explained the observed increase in monocyte recruitment. Thus SAA’s
elevation in the acute inflammatory response following MI could certainly
contribute to accelerated atherosclerosis (78). It is also well established beyond
just myocardial infarction that brief but significant episodes of in-hospital
inflammation increases mortality after discharge. Brinkman et al analyzed data
from intensive care units (ICU) which treated patients admitted for many different
illnesses. They determined that post-discharge mortality was much higher for
ICU discharged patients than age and gender matched non hospitalized
individuals (100). Thus, we propose that beyond indicating risk, elevated
plasma SAA plays a causal role in atherosclerosis development and prevention
of increased SAA may be a therapeutic target. A number of currently available
agents can lower SAA including statins. Individuals with a history of myocardial
infarction and elevated plasma SAA are at greater risk for a second
cardiovascular event than similar patients with lower SAA. However, treatment
with pravastatin reduced the increased risk, perhaps in part by lowering SAA,
(though SAA levels were not a specific endpoint of the study and thus were not
individually analyzed) (101). Given the pleiotropic effects of statins it is difficult to
dissect the mechanisms by which they lower CVD risk. However, it is possible
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that beyond lowering LDL cholesterol, statins may have beneficial effects by
lowering SAA. Beyond statins, other approaches have been found to lower SAA,
such as weight loss (72) and aspirin based therapies (102). However, further
clinical research is necessary to validate SAA as a therapeutic target in humans,
and to determine if therapies targeted specifically to elevated SAA in humans can
be protective.
To summarize, we have shown that both sustained and brief elevations of SAA
result in increased atherosclerosis. We propose that SAA is increasing vascular
biglycan content, resulting in increased lipid retention in the vasculature leading
to increased atherosclerosis. To examine the specific role of increased vascular
biglycan independent of manipulation to plasma SAA, we developed a mouse
model overexpressing biglycan under the control of the smooth muscle α actin
promoter.
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Chapter 5: Biglycan overexpression and atherosclerosis
5.1

Results
In our models of sustained and briefly increased SAA, mice developed

increased atherosclerosis. Biglycan, whose vascular content is increased by
SAA, is thought to play a central role in the development of atherosclerosis by
retaining apolipoprotein B containing lipoproteins in the subendothelial space of
atherosclerosis prone arteries. The purpose of the following experiment was to
determine if increased biglycan, such as seen following an increase in SAA, was
individually sufficient to increase atherosclerosis, independent of any potential
confounding factors introduced by elevated SAA. This study utilized the biglycan
transgenic mouse. For a detailed description of the mouse model, please review
section 2.1, Murine models. At eight weeks of age, male and female biglycan
transgenic x ldlr-/- and control mice were fed western diet for 12 weeks. The
presence or absence of the transgene had no effect on body weight; however,
male mice significantly out gained females in both genotypes (Figure 5.1).
Similar to body weights, the presence of the transgene did not affect total
cholesterol; however, there was a significant difference between male and
female mice (Figure 5.2A). Interestingly, the transgene did affect plasma
triglycerides. Gender as well as genotype resulted in significant changes; again
males had higher triglycerides as did mice not carrying the transgene (Figure
5.2B). FPLC fractionation revealed that lipoprotein profiles did not differ between
genotypes (Figure 5.3). TGF-β was elevated with western diet, but did not differ
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between transgenic and non-transgenic mice (Figure 5.4). Atherosclerosis was
analyzed at three sites; the aortic intimal surface, the aortic sinus and the
brachiocephalic artery. There were no differences in atherosclerotic lesion area
between genders, so male and female mice within genotypes were combined for
analysis. Biglycan transgenic mice had increased atherosclerosis on the aortic
intimal surface (Figure 5.5A, p<0.05) and in the aortic sinus (Figure 5.5B,
p<0.006). There was no difference in atherosclerosis measured in the
brachiocephalic artery (Figure 5.5C) after 12 weeks; however, there was a trend
towards increased atherosclerosis in the brachiocephalic artery in mice analyzed
after four weeks of diet (data not shown). Such regional and chronological
differences in the development of atherosclerosis are well described in the
literature and could certainly explain the lack of atherosclerosis in the
brachiocephalic artery (103).

Immunohistochemical analysis of aortic root sections demonstrated
increased biglycan content in transgenic mice (figure 5.6A). Vascular biglycan
content was measured by western blot (Figure 5.6B) and was increased in
transgenic mice, which correlated with the aortic sinus lesion area (Figure 5.6C,
p<0.0001). Biglycan is thought to be a key mediator of lipid retention in the
vessel wall, so aortic root sections were double labeled with biglycan and apoB
antibodies. Mice transgenic for biglycan had increased co-localization with apoB
containing lipoproteins (Figure 5.7). To further test the effect of increased
vascular biglycan, vascular smooth muscle cells were cultured from transgenic
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and wildtype aortas and incubated with fluorescently labeled LDL. There was a
strong trend towards increased binding in cells from mice possessing the
biglycan transgene; however, it did not reach significance (Figure 5.8).
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Figure 5-1: Biglycan transgenic male mice gained less weight than
control males; however, genotype did not affect female
weight gain
Biglycan transgenic x ldlr-/- and control mice were fed a western diet for 12
weeks (Control male, closed square; Control female, open square; transgenic
male, closed circle; transgenic female, open circle). Body weight was measured
at the indicated timepoints throughout the study. Control male mice gained
significantly more weight by week 8 compared to biglycan transgenic mice. This
effect persisted for the duration of the study. Body weight in female control mice
did not differ from biglycan transgenic females at any time throughout the study.
Data shown is mean ± SEM for n=11-16 per group analyzed by two-way
repeated measures ANOVA with Bonferroni multiple comparisons. * p<0.05, **
p<0.001
.
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Figure 5-2: Biglycan transgenic mice had lower triglycerides compared
to control mice; however, there was no difference in
cholesterol
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12
weeks. Plasma collected at the end of 12 weeks was analyzed for cholesterol
and triglycerides. Cholesterol did not differ between transgenic and control mice;
however, male transgenic mice did have higher total cholesterol than female
transgenic mice (A). Data shown is mean ± SEM for n=12-16 mice per group, **
p<0.01. Triglycerides differed between transgenic and control mice, between
male and female transgenic mice, and between male and female control mice
(B). Data shown is mean ± SEM for n=12-16 mice per group. Data analyzed by
two-way ANOVA with Bonferroni multiple comparisons. **p<0.01, ***p<0.001.
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Figure 5-3: Lipoprotein cholesterol distribution did not differ
between biglycan transgenic and control mice.
Biglycan transgenic (BGNtg, closed circles) and control (open squares) mice
were fed a western diet for 12 weeks. Terminal plasma samples were
separated by fast performance liquid chromatography to analyze lipoprotein
distribution. No difference was observed between transgenic animals (black
circle) and controls (open squares). Data shown is mean ± SEM for n=3-4
mice per group.
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Figure 5-4: TGF-β measured after 12 weeks on study did not differ
between biglycan transgenic and control mice
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12
weeks. Terminal plasma was collected and assayed for TGF-β. No difference
was observed between transgenic and control mice. Data shown is mean ±
SEM for n=9-13 mice per group analyzed by two-way ANOVA with Bonferroni
multiple comparisons.
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Figure 5-5: Biglycan transgenic mice had increased atherosclerosis in the
aortic sinus and on the aortic intimal surface
Biglycan transgenic (BGNtg, closed circles) and control mice (closed squares)
were fed a western diet for 12 weeks. Transgenic mice had increased
atherosclerosis on the aortic intimal surface (A) and in the aortic sinus (B). There
was no difference atherosclerosis between transgenic and control mice in the
brachiocephalic artery (C). Lesions were analyzed using Nikon NISelements
software. Data points represent individual mice with the horizontal bar
representing means of n =20-25 mice per group analyzed by students t-test.
*p<0.05.
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Figure 5-6: Biglycan transgenic mice had increased vascular
biglycan content which correlated with aortic root lesion
area
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12
weeks. Aortic root sections from biglycan transgenic and control mice were
immunostained for biglycan, revealing a striking increase in biglycan content in
transgenic mice (A). Shown are representative images from n=3-4 mice per
group. Total protein from carotid arteries was immunoblotted for biglycan to
determine the extent of transgene expression. The data revealed an increased
in vascular biglycan content in transgenic mice (B). The magnitude of increased
vascular biglycan correlated strongly with aortic sinus atherosclerosis in both
transgenic and control mice (C, r2=0.29, p<0.0001).
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Figure 5-7: Biglycan and apolipoprotein B co-localized to a greater
extent in biglycan transgenic mice compared to control
mice
Biglycan transgenic and control mice were fed a western diet for 12
weeks. Representative confocal images of a shoulder lesion from
biglycan transgenic (BGNtg) and control mouse aortic root section
(magnified 40x). Apolipoprotein B (apoB) and biglycan (BGN) were
visualized with red and green fluorescent antibodies respectfully. Nuclei
were stained blue with DAPI. Co-localization is indicated by the
presence of yellow in the merged image. Images are representative of
n=4-10 per group. Asterisks indicate the lumen of the vessel.
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Figure 5-8: Vascular smooth muscle cell cultures from biglycan
transgenic mice did not differ in LDL binding compared
to control mice
Vascular smooth muscle cells from biglycan transgenic and control aortas
were cultured in chamber slides to near confluence. Cells were then
incubated with Alexafluor-594 labeled LDL for two hours at 4oC. Bound
LDL was quantified by quantitative fluorescent microscopy and
normalized to total DAPI area. Biglycan transgenic animals had a trend
towards increased LDL binding; however, it did not reach significance.
Data are presented as mean±SEM for n=5-10 regions/condition analyzed
by students t-test.
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5.2

Discussion
Ldlr-/- mice expressing the transgene for human biglycan and wildtype

controls were fed a western diet for 12 weeks. Mice possessing the biglycan
transgene had increased atherosclerosis in the aortic sinus and on the aortic
intimal surface compared to wildtype mice. Atherosclerotic lesion area did not
reach significance in the brachiocephalic artery after 12 weeks of western
diet.

Biglycan has been proposed to be a key mediator of lipid retention in
both murine and human atherosclerosis. It is found in atherosclerotic lesions
and we and others have demonstrated its colocalization with apolipoprotein B
containing lipoproteins. Many mechanisms have been shown to increase
vascular biglycan content. Individuals with diabetes for instance have
increased biglycan expression (104), and peptides and cytokines such as
angiotensin II (105), and serum amyloid A (38) also lead to increased
vascular biglycan content. Biglycan synthesized under stimulation of such
cytokines had longer, more negatively charged glycosaminoglycan side
chains that interacted more strongly with the positively charged amino acid
repeats on the surface of apolipoprotein B (17). However, diabetes and these
cytokines have other potential atherogenic effects. For instance,
hyperglycemia has been shown to down regulate eNOS derived NO in
vascular endothelial cells (106), which in turn led to activation of the NF-kB
inflammatory pathways.

AngII is a small peptide best studied in the renin76

angiotensin system of blood pressure regulation. However, angII has a
potent proinflammatory effect on vascular cells found within lesions leading to
induction of many cytokines linked to the development of atherosclerosis
(107). SAA has been described extensively in this thesis and it too can
stimulate the expression of many proinflammatory cytokines known to
activate cells found in lesions. Thus to truly identify the potential role of
biglycan in the development of atherosclerosis, the biglycan transgenic
mouse model was created. It allowed for the study of lipid retention mediated
by vascular biglycan independent of other confounding factors that could also
stimulate lesion development.

It has been demonstrated that biglycan synthesis under the influence
of inflammatory cytokines has increased glycosaminoglycan (GAG) chain
length with increased sulfate incorporation (38). Here biglycan synthesis was
under the control of the smooth muscle alpha actin promoter and not elevated
cytokines. Thus it could be argued that the study did not accurately reflect
the environment previously described in biglycan mediated lipid retention.
We did not measure GAG chain length or sulfate incorporation in the
transgenic animal. However, this study was performed in ldlr-/- mice fed a
proinflammatory western diet meaning that the mice may have been in an
inflamed state, and biglycan synthesized under these conditions may have
had changes in the GAG chains; however, since control mice were under the
same conditions they would have the same response.
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One potentially confounding factor in the analysis of atherosclerosis in
this study was the elevated triglycerides in the littermate control animals.
Triglycerides are well documented as a marker of cardiovascular disease and
their increase is seen as a robust indication of disease risk (108). Individuals
that receive intensive statin therapy, in which their LDL cholesterol levels
decreased to clinically optimal levels still had continued risk of acute coronary
events if dyslipidemia in the form of hypertriglyceridemia remained (109),
suggesting the elevated triglycerides are an independent risk factor for CVD.
This risk may be due to the association of triglycerides with atherogenic
lipoproteins and lipoprotein remnants, especially those carrying apo C-III
(110). Typically these remnant particles are quickly cleared by the liver;
however, in hypertriglyceridemia, the clearance is greatly reduced and the
accumulation of triglyceride rich particles on endothelial cells has been
documented (111). These particles then translocate to the subendothelial
space, binding proteoglycans in the matrix and enhance the retention of
proatherogenic lipoproteins. Thus the mechanism by which triglycerides may
enhance atherosclerosis is slightly different from traditional lipid retention;
however, the end product is subendothelial lipoprotein particle retention.
Taken together the increased triglycerides supports our model as the
increase in both vascular biglycan and translocation of triglyceride rich
particles ultimately ends with increased lipoprotein retention and increased
transit time in the subendothelial space leading to the milieu that drives the
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inflammatory component of atherosclerosis. These findings lend credence to
triglyceride’s causal role in atherosclerosis; however, clinical data has not fully
supported triglycerides as an independent risk factor (109). Statin
monotherapy has been shown to decrease triglycerides and LDL-C;
however, statins have many functions beyond lipid lowering and a clear
reduction in CVD based explicitly on the reduction in triglycerides has yet to
be proven (112) (113). Other classes of drugs are also effective at lowering
triglycerides. Both niacin and fibrates have been shown to reduce
triglycerides in dyslipidemca individuals. Both drugs in large trials as
monotherapies for the reduction of CVD have been shown to reduce both
triglyceride levels and acute cardiovascular events; however, the effect of
lower triglycerides has not been clearly shown to drive the decrease in CVD
(114) (115) . Given that significantly increased atherosclerosis was observed
in the transgenic animals compared to the wildtype controls whose
triglycerides were elevated, the role of triglycerides will not alter the
conclusion that proteoglycan mediated retention of lipoproteins is responsible
for the increase in atherosclerosis.

The purpose was to determine if increased biglycan content was
individually sufficient to increase atherosclerosis over control mice. The data
indicated that biglycan was increased in transgenic mice as was the extent of
atherosclerotic lesion development. Thus increased biglycan is proatherogenic likely by increasing the retention of proatherogenic lipoproteins.
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This data supports a role for biglycan in the development of atherosclerosis;
however, it remains to be seen whether biglycan is absolutely necessary for
the development of atherosclerosis. To determine this, further studies were
conducted using biglycan/apolipoprotein E double knockout mice injected with
ad-hSAA1 or controls.
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Chapter 6: Biglycan deficiency and atherosclerosis
6.1

Results

Many studies have suggested a proatherogenic role for biglycan;
however, its absolute requirement for the development of atherosclerosis has
not been investigated. Here we investigate the necessity of biglycan in
atherosclerosis. Biglycan deficient mice, five times backcrossed to the low
density lipoprotein receptor knockout mouse on a C57BL/6 background, were
obtained from Williams et al (Thomas Jefferson University, Philadelphia, PA,
USA) and crossed with apoe-/- mice from Jackson Laboratory. Generating
this mouse was challenging as the bgn-/o males carry only a single copy of the
gene for biglycan, located on the X chromosome. In order to generate the
bgn-/- x apoe -/- double knockout mouse, males deficient in bgn-/o were
crossed to female apoe -/- deficient mice establishing biglycan wildtype
males(bgn+/o) and biglycan heterozygous (bgn+/-) females, that were now all
heterozygous for apolipoprotein E (apoe +/-). Male biglycan wildtype by
apolipoprotein E heterozygous (bgn+/o x apoe +/-) were crossed to female
biglycan x apolipoprotein E heterozygous mice (bgn+/- x apoe +/-). The
offspring from this cross provided the first opportunity to establish a male
biglycan knockout mouse that was either deficient or heterozygous for
apolipoprotein E (bgn-/o x apoe +/- or bgn-/o x apoe +/-). The previous cross
also established a female mouse that was heterozygous for biglycan but
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deficient in apolipoprotein E (bgn+/- x apoe -/-). The double knockout mouse
was established by crossing the male biglycan deficient x apolipoprotein
deficient (bgn-/o x apoe -/-) to the female biglycan heterozygous x
apolipoprotein E knockout (bgn+/- x apoe -/-). Littermate control mice were
established by crossing a male mouse possessing a single copy of biglycan
but deficient in apolipoprotein E (bgn+/o x apoe -/-) to a female homozygous for
expression of biglycan while deficient in apolipoprotein E (bgn+/+ x apoe -/-)

There was an immediate and persistent phenotype observed with the
bgn-/- x apoe-/- mice. Approximately 80% of offspring born to bgn-/- x apoe-/females exhibited hydrocephaly and required euthanasia by the third week of
life. However, the 20% of offspring that reached weaning age while
remaining asymptomatic for hydrocephaly appeared to be healthy for the
duration of their life. We have successfully crossed the bgn-/- mouse to the
ldlr-/- mouse for studies investigating the role of biglycan in a model of
angiotensin II mediated atherosclerosis (29). These mice exhibited no
obvious health issues, thus the combination of biglycan deficiency and
hyperlipidemia cannot explain the health issues observed in the bgn-/- x
apoe-/-. This study utilized the bgn-/- x apoe-/-and apoe-/- male mice that
survived to eight weeks of age. Both the bgn-/- x apoe-/-and apoe-/- mice were
injected once with ad-hSAA1 or ad-Null and fed normal rodent chow for 16
weeks. Human SAA increased dramatically in the ad-hSAA1 injected mice
(Figure 6.1 A). Strikingly, bgn-/- x apoe-/-mice receiving ad-hSAA1 had
significantly more atherosclerosis in the aortic sinus compared to bgn-/- x
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apoe-/- ad-Null injected mice (Figure 6.1B). The bgn-/- x apoe-/- mice injected
with ad-hSAA1 had a trend toward increased atherosclerosis on the aortic
intimal surface compared to bgn-/- x apoe-/- ad-Null injected mice (Figure
6.1C).
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Figure 6-1: Biglycan deficiency, combined with elevated hSAA1 resulted
in increased atherosclerosis
bgn-/o x apoe-/- and bgn+/o x apoe-/- were injeced once with ad-hSAA1 or ad-Null (adhSAA1 DKO, closed circle; ad-hSAA1/control, closed square; ad-Null/DKO, open
cirlce; ad-Null/control, open square) and bled at the timepoints indicated. Human
SAA1 was measured by species specific ELISA. Mice receiving ad-hSAA1 had
dramatically elevated human SAA1 (A). Data shown is mean ± SEM for n=3-11 mice
per group. Atherosclerosis, after 16 weeks, was significantly increased in bgn-/- x
apoe-/- ad-hSAA1 injected mice in the aortic sinus (B) Data shown are mean ± SEM
for n=7-9 mice per group, p<0.05. There was a trend towards increased
atherosclerosis in bgn-/- x apoe-/- ad-SAA injected mice on the aortic intimal surface
(C) Data shown is mean ± SEM for n= 6-7 analyzed by two-way ANOVA with
Bonferroni multiple comparisons. *p<0.05
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6.2

Discussion
The analysis of this study was stopped as concerns about the mice

enrolled in the study became more apparent. The bgn-/- x apoe-/- double
knockout mouse was produced in our colony by initially crossing biglycan
deficient males to apolipoprotein E deficient females. As biglycan is an Xlinked gene, generation 1 offspring were all heterozygous or wildtype; the
lines were then split such that knockout and littermate controls were produced
from the same founders. This was the same strategy our lab used to produce
the bgn-/- x ldlr-/- double knockout (93). However, the combination of
biglycan deficiency and apolipoprotein E deficiency resulted in hydrocephaly
rates for pre-weaned double knockout offspring greater than 80%. It took
much longer than initially anticipated to enroll the study because of the
extensive amount of breeding required.

Initial analysis also revealed some atherosclerosis patterns that were
not observed in other studies that made us believe we were observing a
possible “healthy survivor” effect, also known as survivorship bias (116).
This statistical concept can be applied to many fields from finance to metaanalysis of medical studies. Basically we are biasing our data by not
considering the mice that did not survive and thus the probability that they
may have somehow influenced the data differently than what we actually
observed. Given the excessive mortality we may have been sampling a sub-
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population of double knockout mice that was very different from the double
knockout population as a whole, making it impossible to draw conclusions
about the entire population. Both bgn-/- x apoe-/- and apoe-/- mice injected
once with ad-hSAA1 had a profound increase in human SAA levels compared
to mice injected with ad-Null, and the human SAA did not return to baseline
levels for more than 8 weeks. Previous experiments using apoe -/- mice and a
single injection of ad-hSAA1 have consistently shown resolution in human
SAA levels by 10-14 days post injection. Interestingly, in this study, apoe -/mice with a prolonged increase in human SAA did not have increased
atherosclerosis in the aortic sinus or on the aortic intimal surface compared to
ad-Null injected apoe -/- mice. This too is quite different than in previous
studies as ad-hSAA1 injected mice consistently had more atherosclerosis
than ad-Null mice. This study also failed to recapitulate the atherosclerosis
data within the littermate controls. In previous work from our lab, apoe -/mice that received ad-hSAA1 consistently had more atherosclerosis at all
three site of atherosclerosis analysis compared to mice receiving ad-Null.
However, in this study the two groups have almost identical levels of
atherosclerosis in their aortic sinus and on their aortic intimal surface.

The hypothesis that SAA is proatherogenic is supported by not only
this thesis but also by Dong et al that revealed increased SAA alone was
sufficient to increase atherosclerosis (85). Furthermore, we hypothesized that
biglycan deficiency would be atheroprotective. Biglycan is found in both
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murine and human lesions and co-localizes with apolipoprotein B containing
lipoproteins (36). It is the basis for the well supported “response to retention”
hypothesis of atherosclerosis that states that lipoprotein retention by
proteoglycans, particularly biglycan, is an initiating event in the development
of atherosclerosis. Recently we published that increased biglycan resulted in
increased atherosclerosis using a biglycan transgenic model {Chapter 5 &
(93)}. Thus, we hypothesized that the absence of biglycan should attenuate
SAA mediated lesion development. However, data in our bgn-/- x apoe-/- mice
demonstrated that biglycan deficiency in the presence of elevated SAA is
proatherogenic. These mice had significantly more atherosclerosis in the
aortic sinus than controls (p<0.05). There was a trend towards increased
atherosclerosis on the aortic intimal surface that did not reach significance.
This data, though contradictory to our overall hypothesis in the lab that
biglycan is pro-atherogenic, is becoming more supported. In unpublished
data from another study examining biglycan deficiency in diabetic ldlr-/- mice
we observed an increase in atherosclerosis in mice deficient in biglycan
compared to mice expressing bgn regardless of glycemic status (data not
shown). The likely confounding factor in biglycan deficiency seems to be
proteoglycan compensation. Biglycan is a very relevant molecule responsible
for biological processes from initial development in utero through
maintenance of collagen fibers, teeth and bones throughout adult life (30).
Previous work in our lab examined the role of angiotensin II on the
development of atherosclerosis in biglycan deficient and biglycan wildtype
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mice crossed to ldlr-/- mouse on a C57BL/6 background. We demonstrated
that mice lacking biglycan actually developed more atherosclerosis compared
to biglycan wildtype mice. Further analysis revealed that perlecan; another
vascular proteoglycan, is upregulated and co-localizes with apolipoprotein B
containing lipoproteins in the biglycan deficient mice. This perlecan
upregulation is not observed in biglycan wildtype mice nor is it TGF-β
dependent as the treatment of these mice with the TGF-β inhibitory antibody
1D11 did not alter perlecan’s expression (29). These data suggest that
perlecan can compensate for biglycan’s absence by achieving the same if not
greater degree of lipoprotein retention in the vessel wall. However,
interpretation of this data is complicated by the fact that perlecan is thought to
not play a role in the development of human atherosclerosis and is in fact
down regulated in human disease (117).

Another possible contributor to increased atherosclerosis in biglycan
deficiency is TGF-β. Hyperglycemia, increased AngII and increased SAA
have all been shown to increase TGF-β. Interestingly TGF-β is maintained in
its latent state in the matrix by interactions with biglycan (44) and decorin
(118). Thus, the absence of biglycan could allow for increased available
active TGF-β, as we have previously shown (53). However, as discussed in
the introduction section 1.4.1, TGF-β has such complex and interconnected
signaling pathways that deducing its exact role in a particular disease may be
beyond the scope of our current technologies (48).
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These data, though not conclusive, do point to the concept that biglycan may
not be necessary for the development of atherosclerosis. To further
investigate our mechanism for the development of atherosclerosis, the role of
TGF-β was investigated using an apoe-/- mouse model of atherosclerosis
coupled with TGF-β inhibition.
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Chapter 7: The necessity of TGF-β signaling in SAA
mediated atherosclerosis
7.1

Results

We have previously demonstrated that both brief and sustained elevations
of SAA directly increased atherosclerosis. Our data suggests that increased
atherosclerosis resulted from SAA increasing TGF-β which in turn increased
vascular biglycan content followed by an increase in lipid retention. We have
previously shown in vitro that inhibition of TGF-β prevented SAA induction of
vascular biglycan content (38); however, the downstream effect of TGF-β
inhibition on the development of atherosclerosis remains unknown. Thus, we
now aimed to determine the necessity of TGF-β in SAA-induced atherosclerosis.
For this study, eight week old male apoe -/- mice were injected once with
ad-hSAA1 or ad-Null via tail vein method, and simultaneously injected via
intraperotineal route with the TGF-β inhibitory antibody 1D11 or 13C4 control
antibody. Human and murine SAA were measured throughout the study using
species specific ELISA’s. Human SAA increased only in the ad-hSAA1 group
receiving 13C4 control antibody (Figure 7.1 A). Murine SAA did not differ
between groups at any timepoint (Figure 7.1 B). Subsequent data analysis was
stopped given the lack of SAA expression in the ad-hSAA1/1D11 group.
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Certainly the question could be asked as to whether the concurrent
administration of 1D11 with ad-hSAA1 specifically could have resulted in the
inability of the virus to infect the mice. However, we had previously carried out a
very small pilot study investigating SAA’s effect on vascular biglycan content in
the absence of TGF-β signaling. In that study apoe-/- male mice were injected
with ad-hSAA1 or ad-Null and then concurrently injected with either 1D11 or
13C4; and vascular tissues collected 28 days later. This pilot SAA/1D11 study
utilized the same lot of ad-hSAA1 that all other studies presented here utilized.
Plasma was collected for measurement of human SAA and TGF-β at several
early timepoints. Ad-hSAA1 administration increased human SAA to levels well
within what we typically see when administering ad-hSAA1 without 1D11 (Figure
7.2A). The data clearly demonstrates that 1D11 antibody did not affect the
expression of human SAA in these mice. Levels of TGF-β were undetectable in
the mice receiving 1D11 indicating that antibody was fully functional as well
(Figure 7.2A). Furthermore, western blot analysis of aortas taken 28 days after
administration of ad-Null, ad-hSAA1, ad-hSAA1 + 1D11 or ad-hSAA1 + 13C4
revealed a striking decrease in biglycan synthesis in mice receiving 1D11,
compared to mice receiving ad-hSAA1 + 13C4 (Figure 7.2B). So based on this
small study the administration of ad-hSAA1 and 1D11 do not interfere with one
another.
To attempt to resolve this issue, another small study was performed using
eight week old apoe-/- male mice from The Jackson Laboratory (Bar Harbor,
Maine, USA). apoe-/- mice (n=12) were divided into three groups. The first group

91

received a single injection of ad-hSAA1 and acted as a control for the expression
of SAA. The second group was injected with ad-hSAA1 via tail vein and then
concurrently injected with 1D11 antibody via IP route. For 1D11 to truly be an
issue, the antibody would likely have to alter a pathway involved in SAA secretion
from hepatocytes as the virus is being delivered intravenously and would likely
bind to and infect the hepatocytes prior to the antibody being absorbed into the
lymphatics and then systemic circulation where it could interfere with the virus
directly. There are no documented TGF-β dependent SAA secretory pathways
described in the literature so this is either not the issue or would represent a
novel interaction between human SAA and antibodies against murine TGF-β.
The third group was injected with ad-hSAA1 and then 24 hours later received an
IP injection of 1D11. This group investigated the possibility of 1D11 inhibitory
antibody to destabilize SAA in circulation such that it is rapidly cleared. If such
an effect is taking place the SAA levels in this delayed 1D11 group should be
much lower than the ad-hSAA1 only group on day three indicating the increased
SAA clearance. Plasma was analyzed from samples collected on days 0, 1 and
3 to determine the time course expression of human SAA. All three groups had
dramatically, equivalently elevated expression of SAA over the first three days
(Figure 7.3). This experiment demonstrates that 1D11 does not interfere with
SAA expression and thus we have not resolved why the 16 week SAA 1D11
experiment failed. This research is ongoing.
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Figure 7-1: Human SAA1 did not increase in mice concurrently
injected with ad-SAA and TGF-β inhibitory antibody 1D11
apoe-/- mice were injected once with ad-hSAA1 or ad-Null and concurrenlty
injected with either TGF-β inhibitory antibody 1D11 or 13C4 control antibody
(ad-hSAA1/1D11, closed circle; ad-hSAA1/13C4, closed square; adNull/1D11, open cirlce; ad-Null/13C4, open square) and bled at the timepoints
indicated. Human and murine SAA were measured by species specific ELISA.
Only mice receiving ad-hSAA1 + 13C4 had dramatically elevated human
SAA1 (A). Data shown is mean ± SEM for n=3-9 mice per group. Murine SAA
did not differ between groups at any timepoint (B). Data shown is mean ±
SEM for n=2-9 mice per group.
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Figure 7-2: TGF-β inhibitory antibody 1D11 suppressed TGF-β
expression, resulting in decreased vascular biglycan
content in mice concurrently injected with ad-hSAA1
and 1D11 antibody.
apoe-/- male mice, eight weeks of age, were injected with ad-hSAA1 or adNull and simultaneously injected with either the TGF-β inhibitory antibody
1D11 or control antibody 13C4 via IP route. Human SAA (black columns)
was measured by species specific ELISA. No difference in SAA was
detected in mice 1 day after receiving ad-hSAA1 regardless of the presence
or absence of TGF-β antibody (A) Data shown is mean ± SEM for n=4-5 mice
per group analyzed by one-way ANOVA with Tukey’s multiple comparisons.
TGF-β (open columns) was elevated in mice receiving ad-hSAA1 with or
without 13C4 control antibody. However, mice receiving 1D11 antibody had
no detectable TGF-β, similar to ad-Null injected mice (A). Data shown is
mean ± SEM for n=4-5 mice per group analyzed by one-way ANOVA with
Tukey’s multiple comparisons. Aortas were collected 28 days after injections
and immunoblotted for biglycan (BGN) or actin. 1D11 prevented the adhSAA1 induction of vascular biglycan but 13C4 had no effect (B). Each lane
shows protein from an individual mouse representative of n=4-5 mice per
group.
94

Human SAA (mg/L)

100
80
60
40

ad-hSAA1
ad-hSAA1/1D11
ad-hSAA1/delayed 1D11

20
0
0

1

2

3

4

Days
Figure 7-3: TGF-β inhibitory antibody 1D11 did not affect
human SAA expression in ad-SAA injected
mice.
Eight week old male apoe-/- mice were injected with ad-SAA
(closed circle), ad-SAA + 1D11 (open square) or ad-SAA + 1D11
24hrs after ad-SAA (delayed group, closed triangle). Plasma was
drawn at the indicated timepoints and assayed for human SAA.
All mice had rapid induction of human SAA regardless of the
presence or timing of administration of the TGF-β inhibitory 1D11.
Data shown is mean ± SEM for n=4 mice per group.
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7.2

Discussion:

apoe-/- deficient male mice were injected with ad-hSAA1 or ad-Null
concurrently with either TGF-β inhibitory antibody 1D11 or an irrelevant control
antibody 13C4. However, the group receiving ad-hSAA1 concurrently with 1D11
did not have the anticipated increase in human SAA as seen in the ad-hSAA1
mice concurrently injected with 13C4. There are several possible explanations
for this. First could be a problem with the adenovirus’ ability to infect the mice.
The virus is very sensitive to freeze thaw cycles and must be stored correctly,
transported to the animal room correctly and resuspended as close to
administration of the injections as possible. The virus is stored in a -80o freezer.
When aliquots are removed from the freezer, they are immediately placed on dry
ice for transport to the animal facility. In my preparation to do adenoviral
injections, this is always the last step so as to minimize the time the virus is out of
the freezer. Once everything in the animal facility is set-up to perform the
injections the virus is resuspended in sterile saline, then immediately injected into
the animals. This has been my ritual for every set of injections I have done. I
have utilized the tail vein injection procedure for hundreds of injections. I have a
great deal of experience with tail vein injections and make notes as part of the
animal record as to the quality of the injection such that a mouse can be removed
based on poor delivery of the virus on my part. So it does not appear to be a
procedural deficiency that led to the lack of SAA expression. Thus, it is highly
unlikely that one of these steps resulted in the absence of SAA expression. The
adenoviral construct was produced in the Webb lab as previously described (89).
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They have extensive knowledge of large scale adenoviral production and
storage. All viral aliquots are immediately stored in a designated -80 freezer
once prepared. Throughout our lab’s investigation of SAA’s effects on
atherosclerosis we have used aliquots of the same large scale viral prep
produced in the Webb lab. This implies that all steps from production to initial
storage were taken appropriately as we have used dozens of aliquots and had
only one issue potentially linked to their production. Several years ago, we
injected a group of mice with ad-hSAA1 and had most of the mice collapse,
appearing very ill in a short period of time (<10 minutes) post injection. Mice
were given supportive therapy such as warmed 0.9% saline subcutaneously and
monitored. All of the mice recovered after about 2 hours and remained healthy
for the duration of the study they were participating in. One possible explanation
for such a dramatic acute collapse would be LPS contamination in the viral
aliquot likely from a contaminated tube that the viral aliquot was stored in,
although a definitive cause of the animals’ distress was never pinpointed.

It is also worth noting that the mice from both the 1D11 group (which failed
to express human SAA) and the 13C4 groups received ad-hSAA1 from the same
pooled aliquots of virus. The 13C4 group did express SAA so the virus was
obviously sufficiently virulent to infect the mice. This implies that every step prior
to injection was done accordingly and the problem with ad-hSAA1 expression in
the 1D11 group lies elsewhere.
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In my thesis work and the pilot SAA/1D11 study mentioned above, the
1D11 antibody was from the same manufacturer, though the lots were different.
Of note, we have noticed in the past that manufacturers will change storage
conditions (such as the inclusion of azide in buffer) and not communicate them
well to the end user. It is highly unlikely that this would result in a problem but
certainly worth mentioning. So at this point we have three studies using both adhSAA1 and 1D11 concurrently. Two of the three studies had elevated SAA
expression as would be expected. The third study was designed to investigate
the requirement of TGF-β in SAA mediated atherosclerosis. In that study adhSAA1 and 1D11 antibody were concurrently injected; however, elevation of
human SAA was not achieved, thus no conclusion regarding TGF-β’s role in SAA
mediated atherosclerosis can be made. These results are certainly unsettling
and will constitute a major portion of the future directions of this thesis.
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Chapter 8: Conclusions and future directions
8.1

Conclusions

The work presented in the thesis is summarized in the model below:

Figure 8-1: Working model
The data in this thesis definitively characterizes serum amyloid A as a
proatherogenic cytokine capable of orchestrating vascular wall remodeling. In
both apoe-/- and rag1-/- x apoe-/- male mice, increased SAA led to an increase in
atherosclerosis at three common sites of analysis. This data is supported by
previous work by Dong et al who demonstrated for the first time that chronic
overexpression of SAA by lentiviral transfection accelerated the progression of
atherosclerosis (85). Their conclusions were based on changes to the vascular
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endothelium known to contribute to atherosclerosis such as increased VCAM and
ICAM, leading to increased monocyte adhesion and translocation into the
developing lesion. Here we expanded upon their findings by demonstrating that
chronically elevated SAA, via adenoviral infection, is atherogenic via the
upregulation of vascular biglycan leading to increased lipid retention. Both our
study and Dong et al clearly implicate SAA as a proatherogenic molecule;
however, timing of our observed effects differed greatly from that presented in
Dong’s work. We demonstrated that SAA was acting early to remodel the vessel
wall such that proatherogenic lipoproteins would be retained leading to the
inflammatory infiltration observed by Dong. Taken together these data indicate
that SAA may be mediating the development of atherosclerosis through multiple
mechanisms at multiple distinct developmental timepoints in the disease
progression. Right now there are literally hundreds of millions of people currently
living with diseases that include chronically elevated SAA as a hallmark feature.
These diseases, such as diabetes and obesity confer greater risk of developing
cardiovascular disease compared to healthy age matched individuals, though
that risk remains largely unexplained. Our data demonstrated that chronically
elevated SAA is pro-atherogenic could certainly provide an explanation for their
increased CVD risk and warrants further investigation.

In our preliminary studies we observed increased vascular biglycan
content 28 days after a single transient increase in SAA. Biglycan, stimulated by
SAA has increased GAG chain length and affinity for apolipoprotein B containing
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lipoproteins. As Nakashima demonstrated, lipid retention following increased
matrix deposition precedes inflammatory infiltration into the developing lesion
(15). Interesting was the revelation that even a single transient elevation of SAA
could lead to sustained, stable remodeling of the vasculature such that biglycan
levels were still elevated 16 weeks after the SAA exposure. Furthermore, mice
with only a brief exposure to SAA and subsequent sustained increase in biglycan
displayed increased atherosclerosis compared to mice with no change in SAA.

In both sustained and briefly elevated SAA studies, increased SAA did not
alter lipids or lipoprotein distribution, nor did body weight or other anthropometric
parameters differ.

To further characterize the importance of biglycan in early lesion
development, we developed the biglycan transgenic mouse and crossed it onto
the ldlr-/- background. This model provided a platform to investigate increased
biglycan independent of the potential confounding effects of elevated SAA.
Vascular biglycan content was increased in both male and female transgenic
mice. These mice exhibited a strong correlation between vascular biglycan
content and aortic sinus atherosclerosis and also a striking co-localization of
aortic sinus biglycan and apolipoprotein B containing lipoproteins.

Furthermore, in support of our hypothesis that biglycan is proatherogenic,
biglycan transgenic mice had increased atherosclerosis within the aortic root and
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on the aortic intimal surface compared to their wildtype controls. The increased
atherosclerosis was independent of other risk factors such as altered cholesterol
or lipoprotein distribution.

Interestingly our data also revealed that biglycan, clearly pro-atherogenic
when present, is not absolutely required for the development of atherosclerosis.
bgn-/- mice injected with ad-hSAA1 actually had increased atherosclerosis
compared to bgn-/- mice injected with ad-Null or wildtype mice injected with either
ad-hSAA1 or ad-Null. Superficially this data appears to contradict our working
hypothesis that biglycan is an important molecule in the development of
atherosclerosis; however, the absence of biglycan does not negate the important
pathological role it is playing in atherosclerosis when present. As such, we have
recapitulated this finding in two other models of biglycan deficient
atherosclerosis. In both a biglycan deficient model of AngII-stimulated
atherosclerosis (53) and a biglycan deficient model of diabetes (in preparation),
the lack of biglycan resulted in either no difference or increased atherosclerosis
compared to biglycan wildtype controls, respectfully. The data presented in this
thesis regarding the absence of biglycan appears to support those findings;
however, there are caveats attached to the bgn-/- data (as discussed in chapter 6)
Our studies also demonstrated that apoe-/- VSMC’s treated with murine
SAA and subsequently incubated with alexa-fluor labeled LDL had increased
LDL binding compared to control cells. The increased LDL binding was
ameliorated with cells were concurrently treated with murine SAA and TGF-β
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inhibitory antibody 1D11; implicating TGF-β as an intermediate in SAA stimulated
lipoprotein retention by vascular smooth muscle cell secreted matrix.

8.2

Future directions

8.2.1

Repeat the TGF-β inhibition study, Chapter 7

Our model of SAA mediated increased biglycan leading to increased
vascular lipid retention and increased atherosclerosis remains incomplete.
Previous data from our lab established that SAA acted through TGF-β to
increase biglycan expression as TGF-β inhibition resulted in decreased vascular
biglycan. A thoughtful experiment to clearly establish the role of TGF-β in SAA
mediated biglycan expression was performed. However, post experimental
analysis of human SAA revealed that the group concurrently receiving ad-hSAA1
and the TGF-β inhibitory antibody 1D11 did not express human SAA. A thorough
discussion of this experiment can be found in Chapter 7 (Discussion, page 95).
This data represents the biggest gap in knowledge within this thesis and also
represents the first step in moving forward. To further assess our proposed
mechanism we need to understand TGF-β’s role in SAA mediated
atherosclerosis. Therefore the experiment presented in chapter 7 needs to be
repeated. This data is necessary prior to addressing any additional future
directions with this project.
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8.2.2

Cross the biglycan transgenic mouse to the apoe-/mouse

Beyond addressing the TGF-β inhibition experiments, the fact that the
biglycan transgenic mice presented in Chapter 5 were crossed to the ldlr-/- is the
next issue to resolve. The biglycan transgenic mouse needs to be crossed to the
apoe-/- mouse, thus a direct comparison of non-stimulated, increased vascular
biglycan can be more thoroughly related to the other experiments presented
here, were the mice were all apoe deficient. The current biglycan transgenic
model, crossed to an ldlr -/- mouse, was developed for investigating biglycan
overexpression as a means of furthering research already begun into the role of
angiotensin II increased biglycan expression in the vasculature. It proved to be a
very useful tool for eliminating the confounding effects of angiotensin II which are
many when discussing atherosclerosis development (53). Although apoe-/- and
ldlr -/- mice are considered the gold standards for modeling atherosclerosis and
are quite similar, there are differences worth noting. apoe-/- mice will
spontaneously develop lesions independent of dietary modification, but another
pro-atherogenic insult such as diet is required for atherosclerosis development in
ldlr -/- mice. apoe-/- mice tend to carry the bulk of their cholesterol on remnant
particles whereas ldlr -/- mice utilize LDL for cholesterol transport. However, the
most crucial attribute to apoe-/- lesion development is that it closely mimics the
progression and severity of human lesions; thus, is more representative of the
disease we are ultimately investigating (119). Given that apoe-/- mice carry the
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bulk of their lipid on chylomicrons and VLDL remnants which are predominantly
apoB48 particles, it is plausible that biglycan mediated lipid retention is not the
only mechanism by which lipoproteins are retained in an apoe-/- mouse. Heparin
and lipoprotein lipase have both been implicated in lipid retention as well (120).
As it stands now, biglycan transgenic mice on an ldlr -/- background have more
atherosclerosis independent of other confounding factors, we will need to
conduct experiments in the biglycan transgenic apoe-/- mouse to see if those data
are replicated. The previously proposed experiments would resolve the issues
directly related to the thesis work presented. However, several observations
made within studies related to this thesis and other work being conducted in our
lab introduced questions that should also be investigated as part of a bigger
more comprehensive evaluation of SAA mediated atherosclerosis that was
beyond the scope of this thesis.

8.2.3

Determine the role of perlecan in SAA mediated
atherosclerotic lesions

Our hypothesis that biglycan was the predominant lipid retaining molecule
in the vasculature was brought into question by findings in this thesis and other
work in our lab. Within our SAA model, we demonstrated a significant increase
in atherosclerosis in mice lacking biglycan. In a model of diabetic nephropathy
and one investigating angiotensin II induced atherosclerosis, both using a
biglycan deficient mouse and wildtype controls, the amount of atherosclerosis
was either not different (angiotensin II) or strikingly higher (diabetic model) when
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biglycan was absent. In the model of diabetic nephropathy, male bgn-/- x ldlr-/and bgn wildtype mice were injected with streptozotocin, to induce a type 1
diabetic phenotype, or citrate buffer and maintained on a 0.12% cholesterol diet
for 26 weeks. Atherosclerosis was analyzed in two sites, the aortic intimal
surface and the aortic sinus. In both sites, the extent of atherosclerosis was
significantly greater in the diabetic mice lacking biglycan (manuscript in
preparation). In the model of angiotensin II induced atherosclerosis, bgn-/- x ldlr-/mice were given angII or saline infusion followed by western diet for 6 weeks.
Interestingly the lack of biglycan was not atheroprotective as was hypothesized.
The mice lacking biglycan had the same extent of atherosclerosis in the aortic
sinus and on the aortic intimal surface as the wildtype angII infused mice (29).
We had previously demonstrated that infusion of angII via alzet minipump
increased both biglycan and perlecan expression in mice (34). The angII
mediated increase in perlecan was not TGF-β dependent as mice co-treated with
angII and the TGF-β inhibitory antibody 1D11 only demonstrated reduced
vascular biglycan content, but no effect on perlecan content (29). It is therefore
plausible that biglycan exhibits some as yet described regulatory role over
perlecan expression. Thus, within our SAA model of atherosclerosis, findings
that mice lacking biglycan had increased atherosclerosis could be explained by
increased perlecan content. To address this question, vascular tissues should
be probed for perlecan using multiple approaches including western blot and
immunohistochemistry to determine what is happening to perlecan levels in the
presence or absence of biglycan. However, there is a significant caveat that
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must be considered when addressing perlecan in atherosclerosis. It has also
been shown that, at least in murine lesions, apolipoprotein B containing
lipoproteins colocalize with perlecan (37). However, even though perlecan is the
primary heparan sulfate proteoglycan in human arteries its expression is
markedly decreased within human atherosclerotic lesions (117, 121) .

8.2.4 Determine what role locally synthesized vs. systemic SAA is playing
in the development of atherosclerosis.

Our study focused on SAA1, one of two isoforms of SAA closely
associated with the acute phase response. SAA1 is mainly produced in the liver
then secreted into circulation after hepatic stimulation via inflammatory molecules
(60). SAA’s association with inflammation and its utility as an inflammatory
marker for diseases such as atherosclerosis are based on measuring alterations
in SAA levels in plasma (122). We and others have demonstrated that, when
elevated even briefly, the acute isoforms of SAA are proatherogenic (Chapters 3
& 4, (85). However, the necessity of acute phase isoforms of SAA in the
development of atherosclerosis was recently questioned. Male and female
apoe-/- mice were compared to apoe-/- mice also deficient in both SAA 1.1 and
SAA 2.2. All mice were fed a chow diet for 50 weeks. Atherosclerosis was
analyzed on the arch, thoracic and abdominal intimal surface and no differences
were observed between mice regardless of the presence or absence of SAA.
The experiment was repeated, replacing the normal rodent chow previously used
with western diet for 12 weeks. The results were the same; there were no
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observed differences in atherosclerosis between groups (123). These data
indicate that acute SAA may be important for the progression of early
atherosclerosis; however, it may not be required.

SAA has been found in atherosclerotic lesions of both apoe-/- and ldlr-/mice co-localized with apolipoprotein-AI and apolipoprotein B containing
lipoproteins (83). We have also demonstrated SAA’s presence in lesions of
apoe-/- mice (data not shown); however, the specific isoform of SAA within the
lesion has never been determined. Interestingly, many cell types found in
atherosclerotic lesions have been shown to express SAA including
macrophages, endothelial cells, vascular smooth muscle cells and adipocytes
(124). Thus, further investigation of the lesional content and specific isoforms of
locally synthesized SAA within atherosclerotic lesions would be beneficial. I
propose utilizing laser capture microscopy to investigate lesions of apoe-/- mice
compared to lesions of apoe-/- mice also deficient in SAA 1.1 and SAA 2.1 to
determine if the expression of SAA3, the extrahepatic, acute isoform of SAA in
mice is altered between the different groups. The SAA3 isoform does not
contribute to circulating SAA so its expression levels cannot simply be accessed
by plasma analysis using ELISAs. If SAA3’s expression levels were higher in the
SAA 1.1 and SAA 2.1 deficient mice it would imply that the acute phase SAAs of
hepatic origin may exhibit some down regulation of SAA3 that is not observed
when SAA 1.1 and 2.1 are absent. This could also imply that SAA3 is
conditionally proatherogenic in the absence of SAA 1.1 and 2.1
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